{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:23:19Z","timestamp":1794601399033,"version":"4.9.1"},"reference-count":499,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences (CIFMS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteoarthritis (OA) is a debilitating joint disorder that causes chronic pain, inflammation, and detrimental bone alterations. Despite significant advances in understanding OA pathogenesis, current therapeutic strategies remain inadequate in halting disease progression or providing effective pain relief, highlighting unmet clinical needs. Recent insights into OA nociceptive pathways, inflammatory mediators, and organelle dysfunction have revealed promising therapeutic targets. Specifically, OA progression is driven by mitochondrial dysfunction (marked by accumulated damaged mitochondria with excessive ROS production and impaired ATP synthesis), lysosomal destabilization (due to persistent hydroxyapatite digestion causing acidification loss, membrane permeabilization, and chondrocyte apoptosis), and unresolved ER stress (resulting from compensatory protein overproduction that exacerbates cartilage degradation). In this review, we aim to provide a comprehensive exploration of the nociceptive pathways linking the knee joint to the central nervous system, shedding light on the mechanisms underlying OA-associated pain. We further analyzed pathological changes in bone architecture and chondrocytes, emphasizing the synergistic roles of inflammatory cytokines and organelle-specific dysfunctions. Building on these mechanistic insights, we delineate emerging pharmacological strategies designed to concurrently address inflammatory cascades, restore organelle homeostasis (via mitophagy potentiation, lysosomal integrity preservation, and ER stress alleviation), and attenuate nociceptive signaling\u2014thereby establishing a multimodal therapeutic paradigm to ameliorate both structural degeneration and clinical manifestations of OA. We also highlight advanced organelle-targeted drug delivery systems designed to increase the therapeutic efficacy and stability of these treatments. Collectively, these advancements provide a framework for novel OA interventions.<\/jats:p>","DOI":"10.1038\/s41392-025-02556-6","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:21:09Z","timestamp":1772626869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Osteoarthritis: molecular pathogenesis and potential therapeutic options"],"prefix":"10.1038","volume":"11","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-5293","authenticated-orcid":false,"given":"Tiantai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"2556_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","volume":"8","author":"Q Yao","year":"2023","unstructured":"Yao, Q. et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct. Target. Ther. 8, 56 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2556_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.72","volume":"2","author":"J Martel-Pelletier","year":"2016","unstructured":"Martel-Pelletier, J. et al. Osteoarthritis. Nat. Rev. Dis. Prim. 2, 16072 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2556_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s40744-021-00327-7","volume":"8","author":"F Castro-Dom\u00ednguez","year":"2021","unstructured":"Castro-Dom\u00ednguez, F. et al. Unmet needs in the osteoarthritis chronic moderate to severe pain management in Spain: a real word data study. Rheumatol. Ther. 8, 1113\u20131127 (2021).","journal-title":"Rheumatol. Ther."},{"key":"2556_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41572-025-00594-6","volume":"11","author":"SA Tang","year":"2025","unstructured":"Tang, S. A. et al. Osteoarthritis. Nat. Rev. Dis. Prim. 11, 10 (2025).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2556_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37107","volume":"4","author":"P Jayakumar","year":"2021","unstructured":"Jayakumar, P. et al. Comparison of an artificial intelligence-enabled patient decision aid vs educational material on decision quality, shared decision-making, patient experience, and functional outcomes in adults with knee osteoarthritis: a randomized clinical trial. JAMA Netw. Open. 4, e2037107 (2021).","journal-title":"JAMA Netw. Open."},{"key":"2556_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/os.12535","volume":"11","author":"JW Li","year":"2019","unstructured":"Li, J. W., Ma, Y. S. & Xiao, L. K. Postoperative pain management in total knee arthroplasty. Orthop. Surg. 11, 755\u2013761 (2019).","journal-title":"Orthop. Surg."},{"key":"2556_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.joca.2024.07.014","volume":"32","author":"A Courties","year":"2024","unstructured":"Courties, A. et al. Osteoarthritis year in review 2024: epidemiology and therapy. Osteoarthr. Cartil. 32, 1397\u20131404 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-025-00598-2","volume":"11","author":"L Gummlich","year":"2025","unstructured":"Gummlich, L. & Marshall, L. Osteoarthritis. Nat. Rev. Dis. Prim. 11, 11 (2025).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2556_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.joca.2021.04.020","volume":"30","author":"KD Allen","year":"2022","unstructured":"Allen, K. D., Thoma, L. M. & Golightly, Y. M. Epidemiology of osteoarthritis. Osteoarthr. Cartil. 30, 184\u2013195 (2022).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/BOR.0000000000000985","volume":"36","author":"MCC Minnig","year":"2024","unstructured":"Minnig, M. C. C., Golightly, Y. M. & Nelson, A. E. Epidemiology of osteoarthritis: literature update 2022-2023. Curr. Opin. Rheumatol. 36, 108\u2013112 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2556_CR11","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.joca.2015.03.020","volume":"23","author":"C Reyes","year":"2015","unstructured":"Reyes, C. et al. Socio-economic status and the risk of developing hand, hip or knee osteoarthritis: a region-wide ecological study. Osteoarthr. Cartil. 23, 1323\u20131329 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms24076405","volume":"24","author":"R Giorgino","year":"2023","unstructured":"Giorgino, R. et al. Knee osteoarthritis: epidemiology, pathogenesis, and mesenchymal stem cells: what else is new? An update. Int. J. Mol. Sci. 24, 7 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10067-024-06885-9","volume":"43","author":"H Li","year":"2024","unstructured":"Li, H., Kong, W., Liang, Y. & Sun, H. Burden of osteoarthritis in China, 1990-2019: findings from the Global Burden of Disease Study 2019. Clin. Rheumatol. 43, 1189\u20131197 (2024).","journal-title":"Clin. Rheumatol."},{"key":"2556_CR14","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.autrev.2018.06.002","volume":"17","author":"A Bortoluzzi","year":"2018","unstructured":"Bortoluzzi, A., Furini, F. & Scir\u00e8, C. A. Osteoarthritis and its management\u2014epidemiology, nutritional aspects and environmental factors. Autoimmun. Rev. 17, 1097\u20131104 (2018).","journal-title":"Autoimmun. Rev."},{"key":"2556_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/art.41231","volume":"74","author":"F Pishgar","year":"2022","unstructured":"Pishgar, F. et al. Association between race and radiographic, symptomatic, and clinical hand osteoarthritis: a propensity score-matched study using osteoarthritis initiative data. Arthritis Rheumatol. 74, 453\u2013461 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2020.09.001","volume":"47","author":"LF Callahan","year":"2021","unstructured":"Callahan, L. F., Cleveland, R. J., Allen, K. D. & Golightly, Y. Racial\/ethnic, socioeconomic, and geographic disparities in the epidemiology of knee and hip osteoarthritis. Rheum. Dis. Clin. North Am. 47, 1\u201320 (2021).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"2556_CR17","doi-asserted-by":"crossref","unstructured":"Steinmetz, J. D. et al. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 5, e508\u2013e522 (2023).","DOI":"10.1016\/S2665-9913(23)00163-7"},{"key":"2556_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/bjsports-2018-100022","volume":"53","author":"E Poulsen","year":"2019","unstructured":"Poulsen, E. et al. Knee osteoarthritis risk is increased 4-6 fold after knee injury\u2014a systematic review and meta-analysis. Br. J. Sports Med. 53, 1454\u20131463 (2019).","journal-title":"Br. J. Sports Med."},{"key":"2556_CR19","doi-asserted-by":"publisher","first-page":"103097","DOI":"10.1016\/j.apergo.2020.103097","volume":"86","author":"EFD Canetti","year":"2020","unstructured":"Canetti, E. F. D. et al. Risk factors for development of lower limb osteoarthritis in physically demanding occupations: a systematic review and meta-analysis. Appl. Ergon. 86, 103097 (2020).","journal-title":"Appl. Ergon."},{"key":"2556_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3899\/jrheum.120589","volume":"40","author":"RK Jones","year":"2013","unstructured":"Jones, R. K. et al. A new approach to prevention of knee osteoarthritis: reducing medial load in the contralateral knee. J. Rheumatol. 40, 309\u2013315 (2013).","journal-title":"J. Rheumatol."},{"key":"2556_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrrheum.2015.135","volume":"12","author":"EM Roos","year":"2016","unstructured":"Roos, E. M. & Arden, N. K. Strategies for the prevention of knee osteoarthritis. Nat. Rev. Rheumatol. 12, 92\u2013101 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/bjsm.2010.082321","volume":"45","author":"H Takeda","year":"2011","unstructured":"Takeda, H., Nakagawa, T., Nakamura, K. & Engebretsen, L. Prevention and management of knee osteoarthritis and knee cartilage injury in sports. Br. J. Sports Med. 45, 304\u2013309 (2011).","journal-title":"Br. J. Sports Med."},{"key":"2556_CR23","first-page":"272","volume":"49","author":"LRS de Melo","year":"2020","unstructured":"de Melo, L. R. S. et al. National osteoarthritis strategy brief report: prevention of osteoarthritis. Aust. J. Gen. Pract. 49, 272\u2013275 (2020).","journal-title":"Aust. J. Gen. Pract."},{"key":"2556_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10787-011-0118-0","volume":"20","author":"R Lee","year":"2012","unstructured":"Lee, R. & Kean, W. F. Obesity and knee osteoarthritis. Inflammopharmacology 20, 53\u201358 (2012).","journal-title":"Inflammopharmacology"},{"key":"2556_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrrheum.2012.224","volume":"9","author":"AE Wluka","year":"2013","unstructured":"Wluka, A. E., Lombard, C. B. & Cicuttini, F. M. Tackling obesity in knee osteoarthritis. Nat. Rev. Rheumatol. 9, 225\u2013235 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR26","doi-asserted-by":"publisher","first-page":"222 s","DOI":"10.1093\/ajcn\/82.1.222S","volume":"82","author":"RR Wing","year":"2005","unstructured":"Wing, R. R. & Phelan, S. Long-term weight loss maintenance. Am. J. Clin. Nutr. 82, 222 s\u2013225 s (2005).","journal-title":"Am. J. Clin. Nutr."},{"key":"2556_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.amjmed.2011.02.037","volume":"124","author":"A Thorogood","year":"2011","unstructured":"Thorogood, A. et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am. J. Med. 124, 747\u2013755 (2011).","journal-title":"Am. J. Med."},{"key":"2556_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nrrheum.2010.198","volume":"7","author":"D Heineg\u00e5rd","year":"2011","unstructured":"Heineg\u00e5rd, D. & Saxne, T. The role of the cartilage matrix in osteoarthritis. Nat. Rev. Rheumatol. 7, 50\u201356 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4085\/1062-6050-47.5.06","volume":"47","author":"JM Hootman","year":"2012","unstructured":"Hootman, J. M. & Albohm, M. J. Anterior cruciate ligament injury prevention and primary prevention of knee osteoarthritis. J. Athl. Train. 47, 589\u2013590 (2012).","journal-title":"J. Athl. Train."},{"key":"2556_CR30","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.joca.2021.06.015","volume":"29","author":"JL Whittaker","year":"2021","unstructured":"Whittaker, J. L., Runhaar, J., Bierma-Zeinstra, S. & Roos, E. M. A lifespan approach to osteoarthritis prevention. Osteoarthr. Cartil. 29, 1638\u20131653 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/bjsports-2019-100765","volume":"54","author":"T Lien-Iversen","year":"2020","unstructured":"Lien-Iversen, T. et al. Does surgery reduce knee osteoarthritis, meniscal injury and subsequent complications compared with non-surgery after ACL rupture with at least 10 years follow-up? A systematic review and meta-analysis. Br. J. Sports Med. 54, 592\u2013598 (2020).","journal-title":"Br. J. Sports Med."},{"key":"2556_CR32","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00167-016-4068-3","volume":"24","author":"H Madry","year":"2016","unstructured":"Madry, H. et al. Early osteoarthritis of the knee. Knee Surg. Sports Traumatol. Arthrosc. 24, 1753\u20131762 (2016).","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"2556_CR33","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s10067-016-3299-5","volume":"35","author":"JB Driban","year":"2016","unstructured":"Driban, J. B. et al. Defining and evaluating a novel outcome measure representing end-stage knee osteoarthritis: data from the Osteoarthritis Initiative. Clin. Rheumatol. 35, 2523\u20132530 (2016).","journal-title":"Clin. Rheumatol."},{"key":"2556_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41584-021-00673-4","volume":"17","author":"A Mahmoudian","year":"2021","unstructured":"Mahmoudian, A. et al. Early-stage symptomatic osteoarthritis of the knee\u2014time for action. Nat. Rev. Rheumatol. 17, 621\u2013632 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2020.22171","volume":"325","author":"JN Katz","year":"2021","unstructured":"Katz, J. N., Arant, K. R. & Loeser, R. F. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA 325, 568\u2013578 (2021).","journal-title":"JAMA"},{"key":"2556_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.mcna.2019.10.007","volume":"104","author":"B Abramoff","year":"2020","unstructured":"Abramoff, B. & Caldera, F. E. Osteoarthritis: pathology, diagnosis, and treatment options. Med. Clin. North. Am. 104, 293\u2013311 (2020).","journal-title":"Med. Clin. North. Am."},{"key":"2556_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jconrel.2020.11.007","volume":"328","author":"S Xiao","year":"2020","unstructured":"Xiao, S. & Chen, L. The emerging landscape of nanotheranostic-based diagnosis and therapy for osteoarthritis. J. Control. Release 328, 817\u2013833 (2020).","journal-title":"J. Control. Release"},{"key":"2556_CR38","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.berh.2023.101866","volume":"37","author":"EH Park","year":"2023","unstructured":"Park, E. H. & Fritz, J. The role of imaging in osteoarthritis. Best. Pract. Res. Clin. Rheumatol. 37, 101866 (2023).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"2556_CR39","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","volume":"377","author":"JW Bijlsma","year":"2011","unstructured":"Bijlsma, J. W., Berenbaum, F. & Lafeber, F. P. Osteoarthritis: an update with relevance for clinical practice. Lancet 377, 2115\u20132126 (2011).","journal-title":"Lancet"},{"key":"2556_CR40","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.7150\/thno.16715","volume":"6","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Recent advances in photoacoustic imaging for deep-tissue biomedical applications. Theranostics 6, 2394\u20132413 (2016).","journal-title":"Theranostics"},{"key":"2556_CR41","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11357-022-00525-3","volume":"44","author":"S Drevet","year":"2022","unstructured":"Drevet, S. et al. New imaging tools for mouse models of osteoarthritis. Geroscience 44, 639\u2013650 (2022).","journal-title":"Geroscience"},{"key":"2556_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.joca.2023.12.005","volume":"32","author":"MHJ van den Bosch","year":"2024","unstructured":"van den Bosch, M. H. J., Blom, A. B. & van der Kraan, P. M. Inflammation in osteoarthritis: our view on its presence and involvement in disease development over the years. Osteoarthr. Cartil. 32, 355\u2013364 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR43","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(23)01726-9","volume":"402","author":"M Kloppenburg","year":"2023","unstructured":"Kloppenburg, M. Inflammation is a relevant treatment target in osteoarthritis. Lancet 402, 1725\u20131726 (2023).","journal-title":"Lancet"},{"key":"2556_CR44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrrheum.2010.196","volume":"7","author":"M Kapoor","year":"2011","unstructured":"Kapoor, M. et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33\u201342 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR45","doi-asserted-by":"publisher","first-page":"8293921","DOI":"10.1155\/2020\/8293921","volume":"2020","author":"YY Chow","year":"2020","unstructured":"Chow, Y. Y. & Chin, K. Y. The role of inflammation in the pathogenesis of osteoarthritis. Mediat. Inflamm. 2020, 8293921 (2020).","journal-title":"Mediat. Inflamm."},{"key":"2556_CR46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.apsb.2019.01.015","volume":"9","author":"F Zhou","year":"2019","unstructured":"Zhou, F. et al. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-\u03baB\/MAPK signaling and protecting chondrocytes. Acta Pharm. Sin. B. 9, 973\u2013985 (2019).","journal-title":"Acta Pharm. Sin. B."},{"key":"2556_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cells10010092","volume":"10","author":"JW Chiu","year":"2021","unstructured":"Chiu, J. W. et al. IL-1\u03b1 processing, signaling and its role in cancer progression. Cells 10, 92 (2021).","journal-title":"Cells"},{"key":"2556_CR48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrrheum.2010.4","volume":"6","author":"C Gabay","year":"2010","unstructured":"Gabay, C., Lamacchia, C. & Palmer, G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 6, 232\u2013241 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR49","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/BOR.0000000000000266","volume":"28","author":"JM Kahlenberg","year":"2016","unstructured":"Kahlenberg, J. M. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade. Curr. Opin. Rheumatol. 28, 197\u2013203 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2556_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrd1342","volume":"3","author":"M Braddock","year":"2004","unstructured":"Braddock, M. & Quinn, A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 3, 330\u2013339 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2556_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40259-017-0224-7","volume":"31","author":"A Mistry","year":"2017","unstructured":"Mistry, A., Savic, S. & van der Hilst, J. C. H. Interleukin-1 blockade: an update on emerging indications. BioDrugs 31, 207\u2013221 (2017).","journal-title":"BioDrugs"},{"key":"2556_CR52","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2147\/JIR.S348491","volume":"15","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. p38MAPK signaling pathway in osteoarthritis: pathological and therapeutic aspects. J. Inflamm. Res. 15, 723\u2013734 (2022).","journal-title":"J. Inflamm. Res."},{"key":"2556_CR53","doi-asserted-by":"crossref","unstructured":"Molnar, V. et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int. J. Mol. Sci. 22, 9208 (2021).","DOI":"10.3390\/ijms22179208"},{"key":"2556_CR54","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.joca.2020.01.016","volume":"28","author":"MHJ van den Bosch","year":"2020","unstructured":"van den Bosch, M. H. J., van Lent, P. & van der Kraan, P. M. Identifying effector molecules, cells, and cytokines of innate immunity in OA. Osteoarthr. Cartil. 28, 532\u2013543 (2020).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cellsig.2018.10.005","volume":"53","author":"Z Jenei-Lanzl","year":"2019","unstructured":"Jenei-Lanzl, Z., Meurer, A. & Zaucke, F. Interleukin-1\u03b2 signaling in osteoarthritis\u2014chondrocytes in focus. Cell. Signal. 53, 212\u2013223 (2019).","journal-title":"Cell. Signal."},{"key":"2556_CR56","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate, A. et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ. Res. 126, 1260\u20131280 (2020).","journal-title":"Circ. Res."},{"key":"2556_CR57","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","volume":"223","author":"WP Arend","year":"2008","unstructured":"Arend, W. P., Palmer, G. & Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223, 20\u201338 (2008).","journal-title":"Immunol. Rev."},{"key":"2556_CR58","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S1063-4584(03)00149-3","volume":"11","author":"TT Chowdhury","year":"2003","unstructured":"Chowdhury, T. T., Bader, D. L. & Lee, D. A. Dynamic compression counteracts IL-1 beta-induced release of nitric oxide and PGE2 by superficial zone chondrocytes cultured in agarose constructs. Osteoarthr. Cartil. 11, 688\u2013696 (2003).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR59","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/art.41312","volume":"72","author":"RF Loeser","year":"2020","unstructured":"Loeser, R. F. et al. Deletion of JNK enhances senescence in joint tissues and increases the severity of age-related osteoarthritis in mice. Arthritis Rheumatol. 72, 1679\u20131688 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR60","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/10799893.2017.1360353","volume":"37","author":"H-x Ge","year":"2017","unstructured":"Ge, H. -x et al. JNK pathway in osteoarthritis: pathological and therapeutic aspects. J. Recept. Signal Transd. 37, 431\u2013436 (2017).","journal-title":"J. Recept. Signal Transd."},{"key":"2556_CR61","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abf3535","volume":"14","author":"SE Catheline","year":"2021","unstructured":"Catheline, S. E. et al. IKK\u03b2-NF-\u03baB signaling in adult chondrocytes promotes the onset of age-related osteoarthritis in mice. Sci. Signal. 14, eabf3535 (2021).","journal-title":"Sci. Signal."},{"key":"2556_CR62","doi-asserted-by":"publisher","first-page":"10855","DOI":"10.1111\/jcmm.15714","volume":"24","author":"B Qiu","year":"2020","unstructured":"Qiu, B., Xu, X., Yi, P. & Hao, Y. Curcumin reinforces MSC-derived exosomes in attenuating osteoarthritis via modulating the miR-124\/NF-kB and miR-143\/ROCK1\/TLR9 signalling pathways. J. Cell. Mol. Med. 24, 10855\u201310865 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"2556_CR63","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1016\/j.biocel.2013.08.018","volume":"45","author":"S Rigoglou","year":"2013","unstructured":"Rigoglou, S. & Papavassiliou, A. G. The NF-\u03baB signalling pathway in osteoarthritis. Int. J. Biochem. Cell Biol. 45, 2580\u20132584 (2013).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2556_CR64","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","volume":"65","author":"AA Jesus","year":"2014","unstructured":"Jesus, A. A. & Goldbach-Mansky, R. IL-1 blockade in autoinflammatory syndromes. Annu. Rev. Med. 65, 223\u2013244 (2014).","journal-title":"Annu. Rev. Med."},{"key":"2556_CR65","doi-asserted-by":"publisher","first-page":"561459","DOI":"10.1155\/2014\/561459","volume":"2014","author":"P Wojdasiewicz","year":"2014","unstructured":"Wojdasiewicz, P., Poniatowski, \u0141A. & Szukiewicz, D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediat. Inflamm. 2014, 561459 (2014).","journal-title":"Mediat. Inflamm."},{"key":"2556_CR66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","volume":"23","author":"G van Loo","year":"2023","unstructured":"van Loo, G. & Bertrand, M. J. M. Death by TNF: a road to inflammation. Nat. Rev. Immunol. 23, 289\u2013303 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2556_CR67","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","volume":"62","author":"H Zelov\u00e1","year":"2013","unstructured":"Zelov\u00e1, H. & Ho\u0161ek, J. TNF-\u03b1 signalling and inflammation: interactions between old acquaintances. Inflamm. Res. 62, 641\u2013651 (2013).","journal-title":"Inflamm. Res."},{"key":"2556_CR68","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"DI Jang","year":"2021","unstructured":"Jang, D. I. et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int. J. Mol. Sci. 22, 2719 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR69","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/ijms23031481","volume":"23","author":"H Kitaura","year":"2022","unstructured":"Kitaura, H. et al. Role of the interaction of tumor necrosis factor-\u03b1 and tumor necrosis factor receptors 1 and 2 in bone-related cells. Int. J. Mol. Sci. 23, 1481 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR70","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","volume":"29","author":"RF Souza","year":"2023","unstructured":"Souza, R. F., Caetano, M. A. F., Magalh\u00e3es, H. I. R. & Castelucci, P. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J. Gastroenterol. 29, 2733\u20132746 (2023).","journal-title":"World J. Gastroenterol."},{"key":"2556_CR71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/icb.2013.15","volume":"91","author":"EA Moelants","year":"2013","unstructured":"Moelants, E. A., Mortier, A., Van Damme, J. & Proost, P. Regulation of TNF-\u03b1 with a focus on rheumatoid arthritis. Immunol. Cell Biol. 91, 393\u2013401 (2013).","journal-title":"Immunol. Cell Biol."},{"key":"2556_CR72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12016-022-08941-1","volume":"64","author":"F Motta","year":"2023","unstructured":"Motta, F., Barone, E., Sica, A. & Selmi, C. Inflammaging and osteoarthritis. Clin. Rev. Allergy Immunol. 64, 222\u2013238 (2023).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2556_CR73","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1093\/rheumatology\/keac124","volume":"61","author":"T Suto","year":"2022","unstructured":"Suto, T. et al. TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. Rheumatology 61, 4535\u20134546 (2022).","journal-title":"Rheumatology"},{"key":"2556_CR74","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202000373RRRR","volume":"35","author":"J Xiaoshi","year":"2021","unstructured":"Xiaoshi, J. et al. SETD7 mediates the vascular invasion in articular cartilage and chondrocytes apoptosis in osteoarthriis. FASEB J. 35, e21283 (2021).","journal-title":"FASEB J."},{"key":"2556_CR75","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.joca.2004.05.009","volume":"12","author":"MC Honorati","year":"2004","unstructured":"Honorati, M. C., Cattini, L. & Facchini, A. IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes. Osteoarthr. Cartil. 12, 683\u2013691 (2004).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR76","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/annrheumdis-2016-209757","volume":"76","author":"A Latourte","year":"2017","unstructured":"Latourte, A. et al. Systemic inhibition of IL-6\/Stat3 signalling protects against experimental osteoarthritis. Ann. Rheum. Dis. 76, 748\u2013755 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abn7082","volume":"15","author":"Y Liao","year":"2022","unstructured":"Liao, Y. et al. Interleukin-6 signaling mediates cartilage degradation and pain in posttraumatic osteoarthritis in a sex-specific manner. Sci. Signal. 15, eabn7082 (2022).","journal-title":"Sci. Signal."},{"key":"2556_CR78","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","volume":"40","author":"T Kishimoto","year":"2022","unstructured":"Kishimoto, T. & Kang, S. IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu. Rev. Immunol. 40, 323\u2013348 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"2556_CR79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","volume":"70","author":"M Del Giudice","year":"2018","unstructured":"Del Giudice, M. & Gangestad, S. W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav. Immun. 70, 61\u201375 (2018).","journal-title":"Brain Behav. Immun."},{"key":"2556_CR80","doi-asserted-by":"publisher","first-page":"eadd3702","DOI":"10.1126\/scisignal.add3702","volume":"15","author":"M Pacifici","year":"2022","unstructured":"Pacifici, M. Osteoarthritis and chronic pain: interleukin-6 as a common denominator and therapeutic target. Sci. Signal. 15, eadd3702 (2022).","journal-title":"Sci. Signal."},{"key":"2556_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2018.10.002","volume":"44","author":"T Wang","year":"2018","unstructured":"Wang, T. & He, C. Pro-inflammatory cytokines: the link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 44, 38\u201350 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2556_CR82","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"10","author":"T Tanaka","year":"2018","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Interleukin (IL-6) immunotherapy. Cold Spring Harb. Perspect. Biol. 10, a028456 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2556_CR83","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335\u2013345 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR84","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/1873-3468.14220","volume":"596","author":"S Rose-John","year":"2022","unstructured":"Rose-John, S. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer. FEBS Lett. 596, 557\u2013566 (2022).","journal-title":"FEBS Lett."},{"key":"2556_CR85","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones, S. A. & Jenkins, B. J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat. Rev. Immunol. 18, 773\u2013789 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2556_CR86","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/rheumatology\/keaa248","volume":"59","author":"R Wiegertjes","year":"2020","unstructured":"Wiegertjes, R., van de Loo, F. A. J. & Blaney Davidson, E. N. A roadmap to target interleukin-6 in osteoarthritis. Rheumatology 59, 2681\u20132694 (2020).","journal-title":"Rheumatology"},{"key":"2556_CR87","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran, P. et al. The balance of interleukin (IL)-6, IL-6\u00b7soluble IL-6 receptor (sIL-6R), and IL-6\u00b7sIL-6R\u00b7sgp130 complexes allows simultaneous classic and trans-signaling. J. Biol. Chem. 293, 6762\u20136775 (2018).","journal-title":"J. Biol. Chem."},{"key":"2556_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara, M. et al. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. 122, 143\u2013159 (2012).","journal-title":"Clin. Sci."},{"key":"2556_CR89","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2018.04.004","volume":"41","author":"N Unver","year":"2018","unstructured":"Unver, N. & McAllister, F. IL-6 family cytokines: key inflammatory mediators as biomarkers and potential therapeutic targets. Cytokine Growth Factor Rev. 41, 10\u201317 (2018).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2556_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/ar4107","volume":"14","author":"AI Tsuchida","year":"2012","unstructured":"Tsuchida, A. I. et al. Interleukin-6 is elevated in synovial fluid of patients with focal cartilage defects and stimulates cartilage matrix production in an in vitro regeneration model. Arthritis Res. Ther. 14, R262 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"2556_CR91","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.joca.2021.10.009","volume":"30","author":"D Liu","year":"2022","unstructured":"Liu, D. et al. Mitochondrial quality control in cartilage damage and osteoarthritis: new insights and potential therapeutic targets. Osteoarthr. Cartil. 30, 395\u2013405 (2022).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR92","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00018-020-03497-9","volume":"77","author":"Y He","year":"2020","unstructured":"He, Y. et al. The role of SIRT3-mediated mitochondrial homeostasis in osteoarthritis. Cell. Mol. Life Sci. 77, 3729\u20133743 (2020).","journal-title":"Cell. Mol. Life Sci."},{"key":"2556_CR93","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.7150\/ijbs.46627","volume":"16","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. The Role of Autophagy and Mitophagy in Bone Metabolic Disorders. Int. J. Biol. Sci. 16, 2675\u20132691 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"2556_CR94","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.cell.2012.02.035","volume":"148","author":"J Nunnari","year":"2012","unstructured":"Nunnari, J. & Suomalainen, A. Mitochondria: in sickness and in health. Cell 148, 1145\u20131159 (2012).","journal-title":"Cell"},{"key":"2556_CR95","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrrheum.2010.213","volume":"7","author":"FJ Blanco","year":"2011","unstructured":"Blanco, F. J., Rego, I. & Ruiz-Romero, C. The role of mitochondria in osteoarthritis. Nat. Rev. Rheumatol. 7, 161\u2013169 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR96","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbi.2022.02.015","volume":"102","author":"J Sun","year":"2022","unstructured":"Sun, J. et al. Sestrin2 overexpression attenuates osteoarthritis pain via induction of AMPK\/PGC-1\u03b1-mediated mitochondrial biogenesis and suppression of neuroinflammation. Brain Behav. Immun. 102, 53\u201370 (2022).","journal-title":"Brain Behav. Immun."},{"key":"2556_CR97","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/art.39182","volume":"67","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1. Arthritis Rheumatol. 67, 2141\u20132153 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR98","doi-asserted-by":"publisher","first-page":"1169019","DOI":"10.3389\/fphar.2023.1169019","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. PGC-1\u03b1 in osteoarthritic chondrocytes: from mechanism to target of action. Front. Pharmacol. 14, 1169019 (2023).","journal-title":"Front. Pharmacol."},{"key":"2556_CR99","doi-asserted-by":"publisher","first-page":"118602","DOI":"10.1016\/j.lfs.2020.118602","volume":"263","author":"Y He","year":"2020","unstructured":"He, Y., Makarczyk, M. J. & Lin, H. Role of mitochondria in mediating chondrocyte response to mechanical stimuli. Life Sci. 263, 118602 (2020).","journal-title":"Life Sci."},{"key":"2556_CR100","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/biom12101420","volume":"12","author":"Z Zeng","year":"2022","unstructured":"Zeng, Z. et al. Mitophagy\u2014a new target of bone disease. Biomolecules 12, 1420 (2022).","journal-title":"Biomolecules"},{"key":"2556_CR101","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1080\/15548627.2020.1822097","volume":"17","author":"K Sun","year":"2021","unstructured":"Sun, K. et al. Mitophagy in degenerative joint diseases. Autophagy 17, 2082\u20132092 (2021).","journal-title":"Autophagy"},{"key":"2556_CR102","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. The mitophagy pathway and its implications in human diseases. Signal Transduct. Target. Ther. 8, 304 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2556_CR103","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.joca.2006.03.008","volume":"14","author":"MJ L\u00f3pez-Armada","year":"2006","unstructured":"L\u00f3pez-Armada, M. J. et al. Mitochondrial activity is modulated by TNFalpha and IL-1beta in normal human chondrocyte cells. Osteoarthr. Cartil. 14, 1011\u20131022 (2006).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/cdd.2012.81","volume":"20","author":"G Ashrafi","year":"2013","unstructured":"Ashrafi, G. & Schwarz, T. L. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 20, 31\u201342 (2013).","journal-title":"Cell Death Differ."},{"key":"2556_CR105","doi-asserted-by":"publisher","first-page":"R170","DOI":"10.1016\/j.cub.2018.01.004","volume":"28","author":"S Pickles","year":"2018","unstructured":"Pickles, S., Vigi\u00e9, P. & Youle, R. J. Mitophagy and quality control mechanisms in mitochondrial. Maint. Curr. Biol. 28, R170\u2013r185 (2018).","journal-title":"Maint. Curr. Biol."},{"key":"2556_CR106","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/cells10020443","volume":"10","author":"AV Poznyak","year":"2021","unstructured":"Poznyak, A. V. et al. Autophagy and mitophagy as essential components of atherosclerosis. Cells 10, 443 (2021).","journal-title":"Cells"},{"key":"2556_CR107","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","volume":"18","author":"SR Bonam","year":"2019","unstructured":"Bonam, S. R., Wang, F. & Muller, S. Lysosomes as a therapeutic target. Nat. Rev. Drug Discov. 18, 923\u2013948 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2556_CR108","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202102001","volume":"220","author":"C Yang","year":"2021","unstructured":"Yang, C. & Wang, X. Lysosome biogenesis: regulation and functions. J. Cell Biol. 220, e202102001 (2021).","journal-title":"J. Cell Biol."},{"key":"2556_CR109","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1194\/jlr.R067520","volume":"57","author":"B Jaishy","year":"2016","unstructured":"Jaishy, B. & Abel, E. D. Lipids, lysosomes, and autophagy. J. Lipid Res. 57, 1619\u20131635 (2016).","journal-title":"J. Lipid Res."},{"key":"2556_CR110","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","volume":"132","author":"B Levine","year":"2008","unstructured":"Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27\u201342 (2008).","journal-title":"Cell"},{"key":"2556_CR111","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-020-03129-z","volume":"591","author":"S Dong","year":"2021","unstructured":"Dong, S. et al. Chaperone-mediated autophagy sustains haematopoietic stem-cell function. Nature 591, 117\u2013123 (2021).","journal-title":"Nature"},{"key":"2556_CR112","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41581-023-00692-2","volume":"19","author":"F Gros","year":"2023","unstructured":"Gros, F. & Muller, S. The role of lysosomes in metabolic and autoimmune diseases. Nat. Rev. Nephrol. 19, 366\u2013383 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"2556_CR113","first-page":"37","volume":"34","author":"T Ye","year":"2024","unstructured":"Ye, T. et al. Lysosomal destabilization: a missing link between pathological calcification and osteoarthritis. Bioact. Mater. 34, 37\u201350 (2024).","journal-title":"Bioact. Mater."},{"key":"2556_CR114","doi-asserted-by":"publisher","first-page":"14867","DOI":"10.1073\/pnas.1111101108","volume":"108","author":"C Jin","year":"2011","unstructured":"Jin, C. et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. Proc. Natl. Acad. Sci. USA 108, 14867\u201314872 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2556_CR115","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.abb.2008.03.037","volume":"473","author":"HK V\u00e4\u00e4n\u00e4nen","year":"2008","unstructured":"V\u00e4\u00e4n\u00e4nen, H. K. & Laitala-Leinonen, T. Osteoclast lineage and function. Arch. Biochem. Biophys. 473, 132\u2013138 (2008).","journal-title":"Arch. Biochem. Biophys."},{"key":"2556_CR116","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nrrheum.2011.165","volume":"7","author":"A So","year":"2011","unstructured":"So, A. & Busso, N. Crystal-gazing into the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 7, 688\u2013689 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR117","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.joca.2020.08.014","volume":"29","author":"MY Ansari","year":"2021","unstructured":"Ansari, M. Y. et al. Lysosomal dysfunction in osteoarthritis and aged cartilage triggers apoptosis in chondrocytes through BAX mediated release of Cytochrome c. Osteoarthr. Cartil. 29, 100\u2013112 (2021).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR118","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1158\/1535-7163.MCT-07-2166","volume":"7","author":"A Yacoub","year":"2008","unstructured":"Yacoub, A. et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7\/IL-24-induced cell killing in primary human glioma cells. Mol. Cancer Ther. 7, 297\u2013313 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"2556_CR119","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00204-012-0878-3","volume":"86","author":"CE Hanzel","year":"2012","unstructured":"Hanzel, C. E., Almeira Gubiani, M. F. & Verstraeten, S. V. Endosomes and lysosomes are involved in early steps of Tl(III)-mediated apoptosis in rat pheochromocytoma (PC12) cells. Arch. Toxicol. 86, 1667\u20131680 (2012).","journal-title":"Arch. Toxicol."},{"key":"2556_CR120","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1023\/A:1020035124855","volume":"7","author":"MD Esposti","year":"2002","unstructured":"Esposti, M. D. The roles of Bid. Apoptosis 7, 433\u2013440 (2002).","journal-title":"Apoptosis"},{"key":"2556_CR121","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.3390\/ijms22158240","volume":"22","author":"M Rose","year":"2021","unstructured":"Rose, M. et al. Direct measurement of the affinity between tbid and bax in a mitochondria-like membrane. Int. J. Mol. Sci. 22, 8240 (2021).","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 1","key":"2556_CR122","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1038\/onc.2009.47","volume":"27","author":"LP Billen","year":"2008","unstructured":"Billen, L. P., Shamas-Din, A. & Andrews, D. W. Bid: a Bax-like BH3 protein. Oncogene 27(Suppl 1), S93\u2013S104 (2008).","journal-title":"Oncogene"},{"key":"2556_CR123","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41584-022-00875-4","volume":"19","author":"I Bernabei","year":"2023","unstructured":"Bernabei, I., So, A., Busso, N. & Nasi, S. Cartilage calcification in osteoarthritis: mechanisms and clinical relevance. Nat. Rev. Rheumatol. 19, 10\u201327 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR124","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/BOR.0b013e32835d8ff8","volume":"25","author":"AM Taylor","year":"2013","unstructured":"Taylor, A. M. Metabolic and endocrine diseases, cartilage calcification and arthritis. Curr. Opin. Rheumatol. 25, 198\u2013203 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2556_CR125","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33744-5","volume":"13","author":"K Nagata","year":"2022","unstructured":"Nagata, K. et al. Runx2 and Runx3 differentially regulate articular chondrocytes during surgically induced osteoarthritis development. Nat. Commun. 13, 6187 (2022).","journal-title":"Nat. Commun."},{"key":"2556_CR126","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11926-009-0020-6","volume":"11","author":"GM McCarthy","year":"2009","unstructured":"McCarthy, G. M. & Cheung, H. S. Point: hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis. Curr. Rheumatol. Rep. 11, 141\u2013147 (2009).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2556_CR127","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/brv.12595","volume":"95","author":"JF Yan","year":"2020","unstructured":"Yan, J. F. et al. Pathological calcification in osteoarthritis: an outcome or a disease initiator?. Biol. Rev. Camb. Philos. Soc. 95, 960\u2013985 (2020).","journal-title":"Biol. Rev. Camb. Philos. Soc."},{"key":"2556_CR128","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000244","volume":"28","author":"AK Rosenthal","year":"2016","unstructured":"Rosenthal, A. K. Articular cartilage vesicles and calcium crystal deposition diseases. Curr. Opin. Rheumatol. 28, 127\u2013132 (2016).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2556_CR129","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/ard-2022-222944","volume":"82","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Stage-specific and location-specific cartilage calcification in osteoarthritis development. Ann. Rheum. Dis. 82, 393\u2013402 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR130","doi-asserted-by":"publisher","first-page":"9776","DOI":"10.3390\/ijms24119776","volume":"24","author":"I Bernabei","year":"2023","unstructured":"Bernabei, I. et al. CD11b deficiency favors cartilage calcification via increased matrix vesicles, apoptosis, and lysyl oxidase activity. Int. J. Mol. Sci. 24, 9776 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR131","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1054\/mehy.2000.1174","volume":"57","author":"DP Naughton","year":"2001","unstructured":"Naughton, D. P. Iron(III)-mediated intra-articular crystal deposition in arthritis: a therapeutic role for iron chelators. Med. Hypotheses 57, 120\u2013122 (2001).","journal-title":"Med. Hypotheses"},{"key":"2556_CR132","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-015-2052-6","volume":"73","author":"DS Schwarz","year":"2016","unstructured":"Schwarz, D. S. & Blower, M. D. The endoplasmic reticulum: structure, function and response to cellular signaling. Cell. Mol. Life Sci. 73, 79\u201394 (2016).","journal-title":"Cell. Mol. Life Sci."},{"key":"2556_CR133","doi-asserted-by":"publisher","first-page":"174903","DOI":"10.1016\/j.ejphar.2022.174903","volume":"922","author":"SY Lee","year":"2022","unstructured":"Lee, S. Y., Wong, P. F., Jamal, J. & Roebuck, M. M. Naturally-derived endoplasmic reticulum stress inhibitors for osteoarthritis?. Eur. J. Pharmacol. 922, 174903 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"2556_CR134","doi-asserted-by":"publisher","first-page":"109880","DOI":"10.1016\/j.cellsig.2020.109880","volume":"78","author":"Y Rellmann","year":"2021","unstructured":"Rellmann, Y., Eidhof, E. & Dreier, R. Review: ER stress-induced cell death in osteoarthritic cartilage. Cell. Signal. 78, 109880 (2021).","journal-title":"Cell. Signal."},{"key":"2556_CR135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2016.192","volume":"13","author":"F Navid","year":"2017","unstructured":"Navid, F. & Colbert, R. A. Causes and consequences of endoplasmic reticulum stress in rheumatic disease. Nat. Rev. Rheumatol. 13, 25\u201340 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR136","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cstres.2024.11.005","volume":"29","author":"Y Lu","year":"2024","unstructured":"Lu, Y. et al. Endoplasmic reticulum stress-mediated apoptosis and autophagy in osteoarthritis: from molecular mechanisms to therapeutic applications. Cell Stress Chaperones 29, 805\u2013830 (2024).","journal-title":"Cell Stress Chaperones"},{"key":"2556_CR137","doi-asserted-by":"publisher","first-page":"40","DOI":"10.32725\/jab.2024.001","volume":"22","author":"DD Liu","year":"2024","unstructured":"Liu, D. D. et al. Endoplasmic reticulum stress-related protein GRP78 and CHOP levels in synovial fluid correlate with disease progression of primary knee osteoarthritis: a cross-sectional study. J. Appl. Biomed. 22, 40\u201348 (2024).","journal-title":"J. Appl. Biomed."},{"key":"2556_CR138","first-page":"54","volume":"10","author":"ZQ Wen","year":"2023","unstructured":"Wen, Z. Q. et al. Insights into the underlying pathogenesis and therapeutic potential of endoplasmic reticulum stress in degenerative musculoskeletal diseases. Mil. Med. Res. 10, 54 (2023).","journal-title":"Mil. Med. Res."},{"key":"2556_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2021.119074","volume":"1868","author":"C Yang","year":"2021","unstructured":"Yang, C. et al. DDIT3\/CHOP promotes autophagy in chondrocytes via SIRT1-AKT pathway. Biochim. Biophys. Acta Mol. Cell Res. 1868, 119074 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"2556_CR140","doi-asserted-by":"publisher","first-page":"123112","DOI":"10.1016\/j.lfs.2024.123112","volume":"357","author":"LJ Soh","year":"2024","unstructured":"Soh, L. J., Lee, S. Y., Roebuck, M. M. & Wong, P. F. Unravelling the interplay between ER stress, UPR and the cGAS-STING pathway: implications for osteoarthritis pathogenesis and treatment strategy. Life Sci. 357, 123112 (2024).","journal-title":"Life Sci."},{"key":"2556_CR141","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/ijms18030665","volume":"18","author":"A Hughes","year":"2017","unstructured":"Hughes, A. et al. Endoplasmic reticulum stress and unfolded protein response in cartilage pathophysiology; contributing factors to apoptosis and osteoarthritis. Int. J. Mol. Sci. 18, 665 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR142","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ceb.2021.02.003","volume":"71","author":"J Stahl-Meyer","year":"2021","unstructured":"Stahl-Meyer, J., Stahl-Meyer, K. & J\u00e4\u00e4ttel\u00e4, M. Control of mitosis, inflammation, and cell motility by limited leakage of lysosomes. Curr. Opin. Cell Biol. 71, 29\u201337 (2021).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2556_CR143","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2019.02.030","volume":"165","author":"G Herrero-Beaumont","year":"2019","unstructured":"Herrero-Beaumont, G. et al. Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression. Biochem. Pharmacol. 165, 24\u201332 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"2556_CR144","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","volume":"23","author":"S Marchi","year":"2023","unstructured":"Marchi, S. et al. Mitochondrial control of inflammation. Nat. Rev. Immunol. 23, 159\u2013173 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2556_CR145","doi-asserted-by":"publisher","first-page":"e49799","DOI":"10.15252\/embr.201949799","volume":"21","author":"JS Riley","year":"2020","unstructured":"Riley, J. S. & Tait, S. W. Mitochondrial DNA in inflammation and immunity. EMBO Rep. 21, e49799 (2020).","journal-title":"EMBO Rep."},{"key":"2556_CR146","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41418-022-01094-w","volume":"30","author":"E Vringer","year":"2023","unstructured":"Vringer, E. & Tait, S. W. G. Mitochondria and cell death-associated inflammation. Cell Death Differ. 30, 304\u2013312 (2023).","journal-title":"Cell Death Differ."},{"key":"2556_CR147","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bbrc.2017.07.094","volume":"491","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Endoplasmic reticulum stress participates in the progress of senescence and apoptosis of osteoarthritis chondrocytes. Biochem. Biophys. Res. Commun. 491, 368\u2013373 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2556_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115343","volume":"206","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Exosome modification to better alleviates endoplasmic reticulum stress induced chondrocyte apoptosis and osteoarthritis. Biochem. Pharmacol. 206, 115343 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"2556_CR149","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature07203","volume":"454","author":"K Zhang","year":"2008","unstructured":"Zhang, K. & Kaufman, R. J. From endoplasmic-reticulum stress to the inflammatory response. Nature 454, 455\u2013462 (2008).","journal-title":"Nature"},{"key":"2556_CR150","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/icb.2011.112","volume":"90","author":"SZ Hasnain","year":"2012","unstructured":"Hasnain, S. Z. et al. The interplay between endoplasmic reticulum stress and inflammation. Immunol. Cell Biol. 90, 260\u2013270 (2012).","journal-title":"Immunol. Cell Biol."},{"key":"2556_CR151","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11926-018-0796-3","volume":"20","author":"F Pan","year":"2018","unstructured":"Pan, F. & Jones, G. Clinical perspective on pain and pain phenotypes in osteoarthritis. Curr. Rheumatol. Rep. 20, 79 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2556_CR152","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/bja\/aen088","volume":"101","author":"R D\u2019Mello","year":"2008","unstructured":"D\u2019Mello, R. & Dickenson, A. H. Spinal cord mechanisms of pain. Br. J. Anaesth. 101, 8\u201316 (2008).","journal-title":"Br. J. Anaesth."},{"key":"2556_CR153","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11914-015-0280-1","volume":"13","author":"RE Miller","year":"2015","unstructured":"Miller, R. E. et al. The role of peripheral nociceptive neurons in the pathophysiology of osteoarthritis pain. Curr. Osteoporos. Rep. 13, 318\u2013326 (2015).","journal-title":"Curr. Osteoporos. Rep."},{"key":"2556_CR154","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11926-018-0716-6","volume":"20","author":"D Syx","year":"2018","unstructured":"Syx, D., Tran, P. B., Miller, R. E. & Malfait, A. M. Peripheral mechanisms contributing to osteoarthritis pain. Curr. Rheumatol. Rep. 20, 9 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2556_CR155","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11914-018-0477-1","volume":"16","author":"TW O\u2019Neill","year":"2018","unstructured":"O\u2019Neill, T. W. & Felson, D. T. Mechanisms of osteoarthritis (OA) pain. Curr. Osteoporos. Rep. 16, 611\u2013616 (2018).","journal-title":"Curr. Osteoporos. Rep."},{"key":"2556_CR156","doi-asserted-by":"publisher","first-page":"8 s","DOI":"10.1097\/PRS.0000000000000682","volume":"134","author":"A Fong","year":"2014","unstructured":"Fong, A. & Schug, S. A. Pathophysiology of pain: a practical primer. Plast. Reconstr. Surg. 134, 8 s\u201314 s (2014).","journal-title":"Plast. Reconstr. Surg."},{"key":"2556_CR157","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.berh.2015.04.017","volume":"29","author":"S Perrot","year":"2015","unstructured":"Perrot, S. Osteoarthritis pain. Best. Pract. Res. Clin. Rheumatol. 29, 90\u201397 (2015).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"2556_CR158","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S0140-6736(05)71086-2","volume":"365","author":"PA Dieppe","year":"2005","unstructured":"Dieppe, P. A. & Lohmander, L. S. Pathogenesis and management of pain in osteoarthritis. Lancet 365, 965\u2013973 (2005).","journal-title":"Lancet"},{"key":"2556_CR159","first-page":"248","volume":"24","author":"F Wang","year":"2024","unstructured":"Wang, F. et al. Nanoparticle-mediated celastrol ER targeting delivery amplify immunogenic cell death in melanoma. J. Adv. Res. 24, 248 (2024).","journal-title":"J. Adv. Res."},{"key":"2556_CR160","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/1073858414567884","volume":"22","author":"RJ Laing","year":"2016","unstructured":"Laing, R. J. & Dhaka, A. ThermoTRPs and Pain. Neuroscientist 22, 171\u2013187 (2016).","journal-title":"Neuroscientist"},{"key":"2556_CR161","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14728222.2020.1815191","volume":"24","author":"D Souza Monteiro de Araujo","year":"2020","unstructured":"Souza Monteiro de Araujo, D., Nassini, R., Geppetti, P. & De Logu, F. TRPA1 as a therapeutic target for nociceptive pain. Expert Opin. Ther. Targets 24, 997\u20131008 (2020).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2556_CR162","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10787-016-0288-x","volume":"24","author":"L Marwaha","year":"2016","unstructured":"Marwaha, L. et al. TRP channels: potential drug target for neuropathic pain. Inflammopharmacology 24, 305\u2013317 (2016).","journal-title":"Inflammopharmacology"},{"key":"2556_CR163","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s13238-017-0395-5","volume":"8","author":"O Gouin","year":"2017","unstructured":"Gouin, O. et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell 8, 644\u2013661 (2017).","journal-title":"Protein Cell"},{"key":"2556_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110391","volume":"271","author":"J Aguilera-Lizarraga","year":"2025","unstructured":"Aguilera-Lizarraga, J. et al. Pro-inflammatory mediators sensitise transient receptor potential melastatin 3 cation channel (TRPM3) function in mouse sensory neurons. Neuropharmacology 271, 110391 (2025).","journal-title":"Neuropharmacology"},{"key":"2556_CR165","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41584-019-0221-y","volume":"15","author":"PG Conaghan","year":"2019","unstructured":"Conaghan, P. G., Cook, A. D., Hamilton, J. A. & Tak, P. P. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat. Rev. Rheumatol. 15, 355\u2013363 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR166","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41583-021-00444-w","volume":"22","author":"G Goodwin","year":"2021","unstructured":"Goodwin, G. & McMahon, S. B. The physiological function of different voltage-gated sodium channels in pain. Nat. Rev. Neurosci. 22, 263\u2013274 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"2556_CR167","doi-asserted-by":"publisher","DOI":"10.1177\/1744806919858801","volume":"15","author":"S Hameed","year":"2019","unstructured":"Hameed, S. Na(v)1.7 and Na(v)1.8: Role in the pathophysiology of pain. Mol. Pain. 15, 1744806919858801 (2019).","journal-title":"Mol. Pain."},{"key":"2556_CR168","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2005.12.001","volume":"27","author":"FF Hefti","year":"2006","unstructured":"Hefti, F. F. et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol. Sci. 27, 85\u201391 (2006).","journal-title":"Trends Pharmacol. Sci."},{"key":"2556_CR169","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-neuro-072116-031121","volume":"40","author":"F Denk","year":"2017","unstructured":"Denk, F., Bennett, D. L. & McMahon, S. B. Nerve growth factor and pain mechanisms. Annu. Rev. Neurosci. 40, 307\u2013325 (2017).","journal-title":"Annu. Rev. Neurosci."},{"key":"2556_CR170","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.3390\/ijms23094642","volume":"23","author":"H Yu","year":"2022","unstructured":"Yu, H. et al. Osteoarthritis pain. Int. J. Mol. Sci. 23, 4642 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR171","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/cells11061035","volume":"11","author":"C Castellini","year":"2022","unstructured":"Castellini, C. et al. The effect of interaction NGF\/p75(NTR) in sperm cells: a rabbit model. Cells 11, 1035 (2022).","journal-title":"Cells"},{"key":"2556_CR172","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40259-021-00504-8","volume":"35","author":"WM Oo","year":"2021","unstructured":"Oo, W. M. & Hunter, D. J. Nerve growth factor (NGF) inhibitors and related agents for chronic musculoskeletal pain: a comprehensive review. BioDrugs 35, 611\u2013641 (2021).","journal-title":"BioDrugs"},{"key":"2556_CR173","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1021\/acs.jmedchem.6b00964","volume":"60","author":"BH Norman","year":"2017","unstructured":"Norman, B. H. & McDermott, J. S. Targeting the nerve growth factor (NGF) pathway in drug discovery. potential applications to new therapies for chronic pain. J. Med. Chem. 60, 66\u201388 (2017).","journal-title":"J. Med. Chem."},{"key":"2556_CR174","doi-asserted-by":"publisher","first-page":"8710","DOI":"10.1523\/JNEUROSCI.3243-20.2021","volume":"41","author":"RM Follis","year":"2021","unstructured":"Follis, R. M. et al. Metabolic control of sensory neuron survival by the p75 neurotrophin receptor in Schwann cells. J. Neurosci. 41, 8710\u20138724 (2021).","journal-title":"J. Neurosci."},{"key":"2556_CR175","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl5716","volume":"8","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. NGF-p75 signaling coordinates skeletal cell migration during bone repair. Sci. Adv. 8, eabl5716 (2022).","journal-title":"Sci. Adv."},{"key":"2556_CR176","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11914-018-0493-1","volume":"16","author":"J Havelin","year":"2018","unstructured":"Havelin, J. & King, T. Mechanisms underlying bone and joint pain. Curr. Osteoporos. Rep. 16, 763\u2013771 (2018).","journal-title":"Curr. Osteoporos. Rep."},{"key":"2556_CR177","first-page":"75","volume":"207","author":"LH Haber","year":"1982","unstructured":"Haber, L. H., Moore, B. D. & Willis, W. D. Electrophysiological response properties of spinoreticular neurons in the monkey. J. Clin. Neurol. 207, 75\u201384 (1982).","journal-title":"J. Clin. Neurol."},{"key":"2556_CR178","first-page":"543","volume":"188","author":"WD Willis","year":"1979","unstructured":"Willis, W. D., Kenshalo, D. R. Jr. & Leonard, R. B. The cells of origin of the primate spinothalamic tract. J. Clin. Neurol. 188, 543\u2013573 (1979).","journal-title":"J. Clin. Neurol."},{"key":"2556_CR179","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1172\/JCI42843","volume":"120","author":"AE Dubin","year":"2010","unstructured":"Dubin, A. E. & Patapoutian, A. Nociceptors: the sensors of the pain pathway. J. Clin. Investig. 120, 3760\u20133772 (2010).","journal-title":"J. Clin. Investig."},{"key":"2556_CR180","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1460-9568.2010.07351.x","volume":"32","author":"XJ Liu","year":"2010","unstructured":"Liu, X. J. & Salter, M. W. Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn. Eur. J. Neurosci. 32, 278\u2013289 (2010).","journal-title":"Eur. J. Neurosci."},{"key":"2556_CR181","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell, F. A. et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94, 1099\u20131142 (2014).","journal-title":"Physiol. Rev."},{"key":"2556_CR182","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00441-018-2922-y","volume":"375","author":"W Zieglg\u00e4nsberger","year":"2019","unstructured":"Zieglg\u00e4nsberger, W. Substance P and pain chronicity. Cell Tissue Res. 375, 227\u2013241 (2019).","journal-title":"Cell Tissue Res."},{"key":"2556_CR183","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neuron.2019.01.034","volume":"101","author":"E Navratilova","year":"2019","unstructured":"Navratilova, E. & Porreca, F. Substance P and inflammatory pain: getting it wrong and right simultaneously. Neuron 101, 353\u2013355 (2019).","journal-title":"Neuron"},{"key":"2556_CR184","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"AF Russo","year":"2015","unstructured":"Russo, A. F. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu. Rev. Pharmacol. Toxicol. 55, 533\u2013552 (2015).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2556_CR185","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nrrheum.2014.47","volume":"10","author":"M Thakur","year":"2014","unstructured":"Thakur, M., Dickenson, A. H. & Baron, R. Osteoarthritis pain: nociceptive or neuropathic?. Nat. Rev. Rheumatol. 10, 374\u2013380 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR186","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.3390\/ijms21238882","volume":"21","author":"R Ju\u00e1rez-Contreras","year":"2020","unstructured":"Ju\u00e1rez-Contreras, R. et al. TRPV1 channel: a noxious signal transducer that affects mitochondrial function. Int. J. Mol. Sci. 21, 8882 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03792-8","volume":"12","author":"Z Lv","year":"2021","unstructured":"Lv, Z. et al. TRPV1 alleviates osteoarthritis by inhibiting M1 macrophage polarization via Ca(2+)\/CaMKII\/Nrf2 signaling pathway. Cell Death Dis. 12, 504 (2021).","journal-title":"Cell Death Dis."},{"key":"2556_CR188","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/ijms24010185","volume":"24","author":"V Vestuto","year":"2022","unstructured":"Vestuto, V. et al. New frontiers on ER stress modulation: are TRP channels the leading actors?. Int. J. Mol. Sci. 24, 185 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR189","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/cells12182322","volume":"12","author":"N Tessier","year":"2023","unstructured":"Tessier, N. et al. TRPV1 channels are new players in the reticulum-mitochondria Ca(2+) coupling in a rat cardiomyoblast cell line. Cells 12, 2322 (2023).","journal-title":"Cells"},{"key":"2556_CR190","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ceca.2016.02.012","volume":"60","author":"P Sukumaran","year":"2016","unstructured":"Sukumaran, P., Schaar, A., Sun, Y. & Singh, B. B. Functional role of TRP channels in modulating ER stress and Autophagy. Cell Calcium 60, 123\u2013132 (2016).","journal-title":"Cell Calcium"},{"key":"2556_CR191","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41594-018-0148-z","volume":"25","author":"X Zhang","year":"2018","unstructured":"Zhang, X., Hu, M., Yang, Y. & Xu, H. Organellar TRP channels. Nat. Struct. Mol. Biol. 25, 1009\u20131018 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2556_CR192","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1083\/jcb.201610067","volume":"215","author":"M Gu","year":"2016","unstructured":"Gu, M. & Xu, H. A painful TR(i)P to lysosomes. J. Cell Biol. 215, 309\u2013312 (2016).","journal-title":"J. Cell Biol."},{"key":"2556_CR193","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1083\/jcb.201603081","volume":"215","author":"S Shang","year":"2016","unstructured":"Shang, S. et al. Intracellular TRPA1 mediates Ca2+ release from lysosomes in dorsal root ganglion neurons. J. Cell Biol. 215, 369\u2013381 (2016).","journal-title":"J. Cell Biol."},{"key":"2556_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102083","volume":"92","author":"S Chauhan","year":"2025","unstructured":"Chauhan, S. et al. Muscarinic acetylcholine type 1 receptor antagonism activates TRPM3 to augment mitochondrial function and drive axonal repair in adult sensory neurons. Mol. Metab. 92, 102083 (2025).","journal-title":"Mol. Metab."},{"key":"2556_CR195","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10571-020-00924-0","volume":"41","author":"RG Mira","year":"2021","unstructured":"Mira, R. G. & Cerpa, W. Building a bridge between NMDAR-mediated excitotoxicity and mitochondrial dysfunction in chronic and acute diseases. Cell. Mol. Neurobiol. 41, 1413\u20131430 (2021).","journal-title":"Cell. Mol. Neurobiol."},{"key":"2556_CR196","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ceca.2009.12.010","volume":"47","author":"E Alberdi","year":"2010","unstructured":"Alberdi, E. et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47, 264\u2013272 (2010).","journal-title":"Cell Calcium"},{"key":"2556_CR197","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jneuroim.2017.03.005","volume":"307","author":"Y Dong","year":"2017","unstructured":"Dong, Y., Kalueff, A. V. & Song, C. N-methyl-d-aspartate receptor-mediated calcium overload and endoplasmic reticulum stress are involved in interleukin-1beta-induced neuronal apoptosis in rat hippocampus. J. Neuroimmunol. 307, 7\u201313 (2017).","journal-title":"J. Neuroimmunol."},{"key":"2556_CR198","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.pharmthera.2018.02.015","volume":"187","author":"A Wang","year":"2018","unstructured":"Wang, A., Leong, D. J., Cardoso, L. & Sun, H. B. Nutraceuticals and osteoarthritis pain. Pharmacol. Ther. 187, 167\u2013179 (2018).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.73","volume":"2","author":"L Marshall","year":"2016","unstructured":"Marshall, L. Osteoarthritis. Nat. Rev. Dis. Prim. 2, 16073 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2556_CR200","first-page":"Cd012087","volume":"2","author":"WT Enthoven","year":"2016","unstructured":"Enthoven, W. T. et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst. Rev. 2, Cd012087 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2556_CR201","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2018.0899","volume":"319","author":"EE Krebs","year":"2018","unstructured":"Krebs, E. E. et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 319, 872\u2013882 (2018).","journal-title":"JAMA"},{"key":"2556_CR202","first-page":"71","volume":"59","author":"C Chircov","year":"2018","unstructured":"Chircov, C., Grumezescu, A. M. & Bejenaru, L. E. Hyaluronic acid-based scaffolds for tissue engineering. Rom. J. Morphol. Embryol. 59, 71\u201376 (2018).","journal-title":"Rom. J. Morphol. Embryol."},{"key":"2556_CR203","first-page":"347","volume":"114","author":"C Otto-Lambertz","year":"2017","unstructured":"Otto-Lambertz, C. et al. Periprosthetic infection in joint replacement. Dtsch. Arztebl. Int. 114, 347\u2013353 (2017).","journal-title":"Dtsch. Arztebl. Int."},{"key":"2556_CR204","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41584-025-01257-2","volume":"21","author":"A-M Malfait","year":"2025","unstructured":"Malfait, A.-M. & Obeidat, A. M. Targeting osteoarthritis where it hurts: the osteochondral junction. Nat. Rev. Rheumatol. 21, 319\u2013320 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR205","doi-asserted-by":"publisher","first-page":"19","DOI":"10.29219\/fnr.v64.3525","volume":"64","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Capsaicin has an anti-obesity effect through alterations in gut microbiota populations and short-chain fatty acid concentrations. Food Nutr. Res. 64, 19 (2020).","journal-title":"Food Nutr. Res."},{"key":"2556_CR206","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40265-020-01429-2","volume":"81","author":"M Iftinca","year":"2021","unstructured":"Iftinca, M., Defaye, M. & Altier, C. TRPV1-targeted drugs in development for human pain conditions. Drugs 81, 7\u201327 (2021).","journal-title":"Drugs"},{"key":"2556_CR207","doi-asserted-by":"publisher","first-page":"102447","DOI":"10.1016\/j.coph.2024.102447","volume":"75","author":"AP Koivisto","year":"2024","unstructured":"Koivisto, A. P., Voets, T., Iadarola, M. J. & Szallasi, A. Targeting TRP channels for pain relief: a review of current evidence from bench to bedside. Curr. Opin. Pharmacol. 75, 102447 (2024).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2556_CR208","doi-asserted-by":"publisher","first-page":"107474","DOI":"10.1016\/j.pharmthera.2020.107474","volume":"208","author":"A Garami","year":"2020","unstructured":"Garami, A. et al. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis. Pharmacol. Ther. 208, 107474 (2020).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR209","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000696","volume":"3","author":"P Arsenault","year":"2018","unstructured":"Arsenault, P. et al. NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. Pain. Rep. 3, e696 (2018).","journal-title":"Pain. Rep."},{"key":"2556_CR210","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1365-2125.2011.04040.x","volume":"72","author":"P Round","year":"2011","unstructured":"Round, P., Priestley, A. & Robinson, J. An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br. J. Clin. Pharmacol. 72, 921\u2013931 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2556_CR211","first-page":"Cd007393","volume":"1","author":"S Derry","year":"2017","unstructured":"Derry, S. et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 1, Cd007393 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2556_CR212","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/art.40894","volume":"71","author":"RM Stevens","year":"2019","unstructured":"Stevens, R. M. et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 71, 1524\u20131533 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR213","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.3390\/molecules27175428","volume":"27","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Identification of a partial and selective TRPV1 agonist CPIPC for alleviation of inflammatory pain. Molecules 27, 5428 (2022).","journal-title":"Molecules"},{"key":"2556_CR214","doi-asserted-by":"publisher","first-page":"107743","DOI":"10.1016\/j.pharmthera.2020.107743","volume":"220","author":"V Arora","year":"2021","unstructured":"Arora, V., Campbell, J. N. & Chung, M. K. Fight fire with fire: neurobiology of capsaicin-induced analgesia for chronic pain. Pharmacol. Ther. 220, 107743 (2021).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR215","doi-asserted-by":"publisher","first-page":"15042","DOI":"10.3390\/ijms242015042","volume":"24","author":"A Szallasi","year":"2023","unstructured":"Szallasi, A. Resiniferatoxin: nature\u2019s precision medicine to silence TRPV1-positive afferents. Int. J. Mol. Sci. 24, 15042 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR216","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1021\/acs.jmedchem.9b01046","volume":"63","author":"J Ann","year":"2020","unstructured":"Ann, J. et al. Discovery of nonpungent transient receptor potential vanilloid 1 (TRPV1) Agonist as strong topical analgesic. J. Med. Chem. 63, 418\u2013424 (2020).","journal-title":"J. Med. Chem."},{"key":"2556_CR217","doi-asserted-by":"publisher","first-page":"115392","DOI":"10.1016\/j.ejmech.2023.115392","volume":"257","author":"Z Hu","year":"2023","unstructured":"Hu, Z. et al. Transient receptor potential ankyrin 1 (TRPA1) modulators: recent update and future perspective. Eur. J. Med. Chem. 257, 115392 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"2556_CR218","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1146\/annurev-pharmtox-010919-023238","volume":"61","author":"D Bamps","year":"2021","unstructured":"Bamps, D., Vriens, J., de Hoon, J. & Voets, T. TRP channel cooperation for nociception: therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 61, 655\u2013677 (2021).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2556_CR219","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pharmthera.2011.10.008","volume":"133","author":"EL Andrade","year":"2012","unstructured":"Andrade, E. L., Meotti, F. C. & Calixto, J. B. TRPA1 antagonists as potential analgesic drugs. Pharmacol. Ther. 133, 189\u2013204 (2012).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR220","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.pain.2012.01.022","volume":"153","author":"A Okun","year":"2012","unstructured":"Okun, A. et al. Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain 153, 924\u2013933 (2012).","journal-title":"Pain"},{"key":"2556_CR221","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.3390\/ijms22073614","volume":"22","author":"H Kanda","year":"2021","unstructured":"Kanda, H. et al. Atractylodin produces antinociceptive effect through a long-lasting TRPA1 channel activation. Int. J. Mol. Sci. 22, 3614 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR222","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/md20070465","volume":"20","author":"YA Logashina","year":"2022","unstructured":"Logashina, Y. A. et al. Analysis of structural determinants of peptide MS 9a-1 essential for potentiating of TRPA1 channel. Mar. Drugs 20, 465 (2022).","journal-title":"Mar. Drugs"},{"key":"2556_CR223","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph10020037","volume":"10","author":"AD Weyer","year":"2017","unstructured":"Weyer, A. D. & Lehto, S. G. Development of TRPM8 antagonists to treat chronic pain and migraine. Pharmaceuticals 10, 37 (2017).","journal-title":"Pharmaceuticals"},{"key":"2556_CR224","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-cellbio-101011-155833","volume":"29","author":"D Julius","year":"2013","unstructured":"Julius, D. TRP channels and pain. Annu. Rev. Cell. Dev. Biol. 29, 355\u2013384 (2013).","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"2556_CR225","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.pain.2013.06.043","volume":"154","author":"B Liu","year":"2013","unstructured":"Liu, B. et al. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain 154, 2169\u20132177 (2013).","journal-title":"Pain"},{"key":"2556_CR226","doi-asserted-by":"publisher","first-page":"10057","DOI":"10.3390\/ijms241210057","volume":"24","author":"L Halonen","year":"2023","unstructured":"Halonen, L. et al. Human osteoarthritic chondrocytes express nineteen different TRP-genes-TRPA1 and TRPM8 as potential drug targets. Int. J. Mol. Sci. 24, 10057 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR227","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00281-015-0526-0","volume":"38","author":"Y Dai","year":"2016","unstructured":"Dai, Y. TRPs and pain. Semin. Immunopathol. 38, 277\u2013291 (2016).","journal-title":"Semin. Immunopathol."},{"key":"2556_CR228","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.pain.2014.07.022","volume":"155","author":"R Patel","year":"2014","unstructured":"Patel, R. et al. Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: a comparison with topical menthol. Pain 155, 2097\u20132107 (2014).","journal-title":"Pain"},{"key":"2556_CR229","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/bph.14177","volume":"175","author":"C De Caro","year":"2018","unstructured":"De Caro, C. et al. Antinociceptive effect of two novel transient receptor potential melastatin 8 antagonists in acute and chronic pain models in rat. Br. J. Pharmacol. 175, 1691\u20131706 (2018).","journal-title":"Br. J. Pharmacol."},{"key":"2556_CR230","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1519\/JPT.0b013e318268dde1","volume":"36","author":"R Topp","year":"2013","unstructured":"Topp, R., Brosky, J. A. Jr. & Pieschel, D. The effect of either topical menthol or a placebo on functioning and knee pain among patients with knee OA. J. Geriatr. Phys. Ther. 36, 92\u201399 (2013).","journal-title":"J. Geriatr. Phys. Ther."},{"key":"2556_CR231","first-page":"171","volume":"10","author":"ER Liman","year":"2014","unstructured":"Liman, E. R. TRP channels: pain enters through the side door. Nat. Cell Biol. 10, 171\u2013172 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2556_CR232","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neuron.2011.02.051","volume":"70","author":"J Vriens","year":"2011","unstructured":"Vriens, J. et al. TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron 70, 482\u2013494 (2011).","journal-title":"Neuron"},{"key":"2556_CR233","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61103","volume":"9","author":"M Mulier","year":"2020","unstructured":"Mulier, M. et al. Upregulation of TRPM3 in nociceptors innervating inflamed tissue. Elife 9, e61103 (2020).","journal-title":"Elife"},{"key":"2556_CR234","first-page":"188","volume":"10","author":"J Vriens","year":"2014","unstructured":"Vriens, J. et al. Opening of an alternative ion permeation pathway in a nociceptor TRP channel. Nat. Cell Biol. 10, 188\u2013195 (2014).","journal-title":"Nat. Cell Biol."},{"key":"2556_CR235","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","volume":"99","author":"DL Bennett","year":"2019","unstructured":"Bennett, D. L. et al. The role of voltage-gated sodium channels in pain signaling. Physiol. Rev. 99, 1079\u20131151 (2019).","journal-title":"Physiol. Rev."},{"key":"2556_CR236","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13543784.2020.1728254","volume":"29","author":"M Kushnarev","year":"2020","unstructured":"Kushnarev, M., Pirvulescu, I. P., Candido, K. D. & Knezevic, N. N. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. Expert Opin. Investig. Drugs 29, 259\u2013271 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2556_CR237","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev.pharmtox.44.101802.121627","volume":"44","author":"J Lai","year":"2004","unstructured":"Lai, J., Porreca, F., Hunter, J. C. & Gold, M. S. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Toxicol. 44, 371\u2013397 (2004).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"2556_CR238","first-page":"314","volume":"6","author":"G Loussouarn","year":"2015","unstructured":"Loussouarn, G. et al. Physiological and pathophysiological insights of Nav1.4 and Nav1.5 comparison. Front. Pharmacol. 6, 314 (2015).","journal-title":"Front. Pharmacol."},{"key":"2556_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113085","volume":"42","author":"B Drouillas","year":"2023","unstructured":"Drouillas, B. et al. Persistent Nav1.1 and Nav1.6 currents drive spinal locomotor functions through nonlinear dynamics. Cell Rep. 42, 113085 (2023).","journal-title":"Cell Rep."},{"key":"2556_CR240","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrn3977","volume":"16","author":"SD Dib-Hajj","year":"2015","unstructured":"Dib-Hajj, S. D., Black, J. A. & Waxman, S. G. NaV1.9: a sodium channel linked to human pain. Nat. Rev. Neurosci. 16, 511\u2013519 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"2556_CR241","first-page":"940","volume":"508","author":"BJ O\u2019Brien","year":"2008","unstructured":"O\u2019Brien, B. J. et al. Tetrodotoxin-resistant voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 are expressed in the retina. J. Clin. Neurol. 508, 940\u2013951 (2008).","journal-title":"J. Clin. Neurol."},{"key":"2556_CR242","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.neuron.2021.03.012","volume":"109","author":"DI MacDonald","year":"2021","unstructured":"MacDonald, D. I. et al. A central mechanism of analgesia in mice and humans lacking the sodium channel Na(V)1.7. Neuron 109, 1497\u20131512.e1496 (2021).","journal-title":"Neuron"},{"key":"2556_CR243","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/biom12111571","volume":"12","author":"AR Reid","year":"2022","unstructured":"Reid, A. R., C\u00f4t\u00e9, P. D. & McDougall, J. J. Long-term blockade of nociceptive Na(v)1.7 channels is analgesic in rat models of knee arthritis. Biomolecules 12, 1571 (2022).","journal-title":"Biomolecules"},{"key":"2556_CR244","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.57656","volume":"9","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Aberrant subchondral osteoblastic metabolism modifies Na(V)1.8 for osteoarthritis. Elife 9, e57656 (2020).","journal-title":"Elife"},{"key":"2556_CR245","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-023-06888-7","volume":"625","author":"W Fu","year":"2024","unstructured":"Fu, W. et al. Na(v)1.7 as a chondrocyte regulator and therapeutic target for osteoarthritis. Nature 625, 557\u2013565 (2024).","journal-title":"Nature"},{"key":"2556_CR246","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00109-017-1599-0","volume":"96","author":"JV Torres-P\u00e9rez","year":"2018","unstructured":"Torres-P\u00e9rez, J. V. et al. The NA(v)1.7 blocker protoxin II reduces burn injury-induced spinal nociceptive processing. J. Mol. Med. (Berl.) 96, 75\u201384 (2018).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"2556_CR247","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuroscience.2015.03.042","volume":"295","author":"W Rahman","year":"2015","unstructured":"Rahman, W. & Dickenson, A. H. Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: an in vivo electrophysiological study in the rat. Neuroscience 295, 103\u2013116 (2015).","journal-title":"Neuroscience"},{"key":"2556_CR248","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81727","volume":"11","author":"PT Nguyen","year":"2022","unstructured":"Nguyen, P. T. et al. Computational design of peptides to target Na(V)1.7 channel with high potency and selectivity for the treatment of pain. Elife 11, e81727 (2022).","journal-title":"Elife"},{"key":"2556_CR249","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar3553","volume":"14","author":"N Schuelert","year":"2012","unstructured":"Schuelert, N. & McDougall, J. J. Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritis. Arthritis Res. Ther. 14, R5 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"2556_CR250","first-page":"450","volume":"15","author":"J Collison","year":"2019","unstructured":"Collison, J. Anti-NGF therapy improves osteoarthritis pain. Nat. Rev. Rheumatol. 15, 450\u2013450 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR251","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jama.2019.8250","volume":"322","author":"JN Katz","year":"2019","unstructured":"Katz, J. N. Tanezumab for painful osteoarthritis. JAMA 322, 30\u201332 (2019).","journal-title":"JAMA"},{"key":"2556_CR252","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/art.39943","volume":"69","author":"P Sanga","year":"2017","unstructured":"Sanga, P. et al. Long-term safety and efficacy of fulranumab in patients with moderate-to-severe osteoarthritis pain: a phase II randomized, double-blind, placebo-controlled extension study. Arthritis Rheumatol. 69, 763\u2013773 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR253","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin, P. et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 71, 1824\u20131834 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR254","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0022-3565(24)38269-2","volume":"289","author":"JB Owolabi","year":"1999","unstructured":"Owolabi, J. B. et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J. Pharmacol. Exp. Ther. 289, 1271\u20131276 (1999).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2556_CR255","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1021\/acs.jmedchem.8b00633","volume":"61","author":"SK Bagal","year":"2018","unstructured":"Bagal, S. K. et al. Discovery of potent, selective, and peripherally restricted pan-Trk kinase inhibitors for the treatment of pain. J. Med. Chem. 61, 6779\u20136800 (2018).","journal-title":"J. Med. Chem."},{"key":"2556_CR256","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.1021\/acs.jmedchem.6b00850","volume":"59","author":"SE Skerratt","year":"2016","unstructured":"Skerratt, S. E. et al. The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain. J. Med. Chem. 59, 10084\u201310099 (2016).","journal-title":"J. Med. Chem."},{"key":"2556_CR257","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/annrheumdis-2014-207203","volume":"75","author":"LN Nwosu","year":"2016","unstructured":"Nwosu, L. N., Mapp, P. I., Chapman, V. & Walsh, D. A. Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis. Ann. Rheum. Dis. 75, 1246\u20131254 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR258","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0165-6147(00)01502-9","volume":"21","author":"R Hill","year":"2000","unstructured":"Hill, R. NK1 (substance P) receptor antagonists-why are they not analgesic in humans?. Trends Pharmacol. Sci. 21, 244\u2013246 (2000).","journal-title":"Trends Pharmacol. Sci."},{"key":"2556_CR259","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.pain.2013.01.002","volume":"154","author":"S Hirsch","year":"2013","unstructured":"Hirsch, S. et al. The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats. Pain 154, 700\u2013707 (2013).","journal-title":"Pain"},{"key":"2556_CR260","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/art.38656","volume":"66","author":"CM Bullock","year":"2014","unstructured":"Bullock, C. M. et al. Peripheral calcitonin gene-related peptide receptor activation and mechanical sensitization of the joint in rat models of osteoarthritis pain. Arthritis Rheumatol. 66, 2188\u20132200 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR261","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00023210-200115010-00004","volume":"15","author":"ME Fundytus","year":"2001","unstructured":"Fundytus, M. E. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 15, 29\u201358 (2001).","journal-title":"CNS Drugs"},{"key":"2556_CR262","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0304-3959(98)00014-1","volume":"75","author":"D Pud","year":"1998","unstructured":"Pud, D. et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 75, 349\u2013354 (1998).","journal-title":"Pain"},{"key":"2556_CR263","doi-asserted-by":"publisher","first-page":"108542","DOI":"10.1016\/j.neuropharm.2021.108542","volume":"191","author":"AC Chin","year":"2021","unstructured":"Chin, A. C. & Lau, A. Y. Structural biology and thermodynamics of GluD receptors. Neuropharmacology 191, 108542 (2021).","journal-title":"Neuropharmacology"},{"key":"2556_CR264","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40263-019-00618-2","volume":"33","author":"D Kreutzwiser","year":"2019","unstructured":"Kreutzwiser, D. & Tawfic, Q. A. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs 33, 347\u2013374 (2019).","journal-title":"CNS Drugs"},{"key":"2556_CR265","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.expneurol.2008.10.018","volume":"215","author":"XX Qu","year":"2009","unstructured":"Qu, X. X. et al. Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp. Neurol. 215, 298\u2013307 (2009).","journal-title":"Exp. Neurol."},{"key":"2556_CR266","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S0165-6147(00)01863-0","volume":"22","author":"BA Chizh","year":"2001","unstructured":"Chizh, B. A., Headley, P. M. & Tzschentke, T. M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci. 22, 636\u2013642 (2001).","journal-title":"Trends Pharmacol. Sci."},{"key":"2556_CR267","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.3390\/nu12082184","volume":"12","author":"HJ Shin","year":"2020","unstructured":"Shin, H. J., Na, H. S. & Do, S. H. Magnesium and Pain. Nutrients 12, 2184 (2020).","journal-title":"Nutrients"},{"key":"2556_CR268","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/ijms24031908","volume":"24","author":"P Cha\u0142upnik","year":"2023","unstructured":"Cha\u0142upnik, P. & Szyma\u0144ska, E. Kainate receptor antagonists: recent advances and therapeutic perspective. Int. J. Mol. Sci. 24, 1908 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR269","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2174\/0929867013372328","volume":"8","author":"BK Kohl","year":"2001","unstructured":"Kohl, B. K. & Dannhardt, G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. 8, 1275\u20131289 (2001).","journal-title":"Curr. Med. Chem."},{"key":"2556_CR270","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neuron.2004.10.029","volume":"44","author":"B Hartmann","year":"2004","unstructured":"Hartmann, B. et al. The AMPA receptor subunits GluR-A and GluR-B reciprocally modulate spinal synaptic plasticity and inflammatory pain. Neuron 44, 637\u2013650 (2004).","journal-title":"Neuron"},{"key":"2556_CR271","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.neuron.2007.06.001","volume":"54","author":"JT Isaac","year":"2007","unstructured":"Isaac, J. T., Ashby, M. C. & McBain, C. J. The role of the GluR2 subunit in AMPA receptor function and synaptic plasticity. Neuron 54, 859\u2013871 (2007).","journal-title":"Neuron"},{"key":"2556_CR272","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1172\/JCI44911","volume":"121","author":"V Gangadharan","year":"2011","unstructured":"Gangadharan, V. et al. Peripheral calcium-permeable AMPA receptors regulate chronic inflammatory pain in mice. J. Clin. Investig. 121, 1608\u20131623 (2011).","journal-title":"J. Clin. Investig."},{"key":"2556_CR273","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/annrheumdis-2013-203670","volume":"74","author":"CS Bonnet","year":"2015","unstructured":"Bonnet, C. S. et al. AMPA\/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Ann. Rheum. Dis. 74, 242\u2013251 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR274","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134055","volume":"5","author":"CS Bonnet","year":"2020","unstructured":"Bonnet, C. S. et al. AMPA\/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis. JCI Insight 5, e134055 (2020).","journal-title":"JCI Insight"},{"key":"2556_CR275","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.pain.2011.01.018","volume":"152","author":"CS Qiu","year":"2011","unstructured":"Qiu, C. S. et al. Antinociceptive effects of MSVIII-19, a functional antagonist of the GluK1 kainate receptor. Pain 152, 1052\u20131060 (2011).","journal-title":"Pain"},{"key":"2556_CR276","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1111\/febs.16081","volume":"289","author":"JV Negrete-D\u00edaz","year":"2022","unstructured":"Negrete-D\u00edaz, J. V., Falc\u00f3n-Moya, R. & Rodr\u00edguez-Moreno, A. Kainate receptors: from synaptic activity to disease. FEBS J. 289, 5074\u20135088 (2022).","journal-title":"FEBS J."},{"key":"2556_CR277","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2174\/138161207780765864","volume":"13","author":"LJ Wu","year":"2007","unstructured":"Wu, L. J., Ko, S. W. & Zhuo, M. Kainate receptors and pain: from dorsal root ganglion to the anterior cingulate cortex. Curr. Pharm. Des. 13, 1597\u20131605 (2007).","journal-title":"Curr. Pharm. Des."},{"key":"2556_CR278","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.coph.2005.08.004","volume":"6","author":"J Lerma","year":"2006","unstructured":"Lerma, J. Kainate receptor physiology. Curr. Opin. Pharmacol. 6, 89\u201397 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2556_CR279","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1021\/jm0491952","volume":"48","author":"E Dominguez","year":"2005","unstructured":"Dominguez, E. et al. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. J. Med. Chem. 48, 4200\u20134203 (2005).","journal-title":"J. Med. Chem."},{"key":"2556_CR280","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.semcdb.2006.10.008","volume":"17","author":"D Bleakman","year":"2006","unstructured":"Bleakman, D., Alt, A. & Nisenbaum, E. S. Glutamate receptors and pain. Semin. Cell Dev. Biol. 17, 592\u2013604 (2006).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2556_CR281","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1097\/j.pain.0000000000000621","volume":"157","author":"S Davidson","year":"2016","unstructured":"Davidson, S. et al. Group II mGluRs suppress hyperexcitability in mouse and human nociceptors. Pain 157, 2081\u20132088 (2016).","journal-title":"Pain"},{"key":"2556_CR282","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pain.2007.08.020","volume":"137","author":"C Goudet","year":"2008","unstructured":"Goudet, C. et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 137, 112\u2013124 (2008).","journal-title":"Pain"},{"key":"2556_CR283","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1124\/jpet.300.1.149","volume":"300","author":"L Zhang","year":"2002","unstructured":"Zhang, L., Lu, Y., Chen, Y. & Westlund, K. N. Group I metabotropic glutamate receptor antagonists block secondary thermal hyperalgesia in rats with knee joint inflammation. J. Pharmacol. Exp. Ther. 300, 149\u2013156 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2556_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2020.100046","volume":"2","author":"CA Ma","year":"2020","unstructured":"Ma, C. A. et al. The association of plasma IL-1Ra and related cytokines with radiographic severity of early knee osteoarthritis. Osteoarthr. Cartil. Open. 2, 100046 (2020).","journal-title":"Osteoarthr. Cartil. Open."},{"key":"2556_CR285","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.joca.2015.08.006","volume":"23","author":"M Attur","year":"2015","unstructured":"Attur, M. et al. Plasma levels of interleukin-1 receptor antagonist (IL1Ra) predict radiographic progression of symptomatic knee osteoarthritis. Osteoarthr. Cartil. 23, 1915\u20131924 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR286","doi-asserted-by":"publisher","DOI":"10.1186\/s40634-016-0054-4","volume":"3","author":"KA Elsaid","year":"2016","unstructured":"Elsaid, K. A., Ubhe, A., Shaman, Z. & D\u2019Souza, G. Intra-articular interleukin-1 receptor antagonist (IL1-ra) microspheres for posttraumatic osteoarthritis: in vitro biological activity and in vivo disease modifying effect. J. Exp. Orthop. 3, 18 (2016).","journal-title":"J. Exp. Orthop."},{"key":"2556_CR287","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.joca.2023.01.573","volume":"31","author":"S Mehta","year":"2023","unstructured":"Mehta, S. et al. Sustained intra-cartilage delivery of interleukin-1 receptor antagonist using cationic peptide and protein-based carriers. Osteoarthr. Cartil. 31, 780\u2013792 (2023).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR288","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/sj.gt.3301608","volume":"9","author":"DD Frisbie","year":"2002","unstructured":"Frisbie, D. D. et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther. 9, 12\u201320 (2002).","journal-title":"Gene Ther."},{"key":"2556_CR289","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/pharmaceutics14091785","volume":"14","author":"J Deng","year":"2022","unstructured":"Deng, J. et al. Anti-inflammatory therapy for temporomandibular joint osteoarthritis using mRNA medicine encoding interleukin-1 receptor antagonist. Pharmaceutics 14, 1785 (2022).","journal-title":"Pharmaceutics"},{"key":"2556_CR290","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/art.40668","volume":"70","author":"AJ Nixon","year":"2018","unstructured":"Nixon, A. J. et al. Disease-modifying osteoarthritis treatment with interleukin-1 receptor antagonist gene therapy in small and large animal models. Arthritis Rheumatol. 70, 1757\u20131768 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR291","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.immuni.2023.05.014","volume":"56","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. Immunity 56, 1485\u20131501.e1487 (2023).","journal-title":"Immunity"},{"key":"2556_CR292","doi-asserted-by":"publisher","DOI":"10.1186\/ar3163","volume":"12","author":"MH Cardiel","year":"2010","unstructured":"Cardiel, M. H. et al. A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res. Ther. 12, R192 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"2556_CR293","doi-asserted-by":"publisher","DOI":"10.1186\/ar3430","volume":"13","author":"SB Cohen","year":"2011","unstructured":"Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"2556_CR294","doi-asserted-by":"publisher","first-page":"115861","DOI":"10.1016\/j.ejmech.2023.115861","volume":"261","author":"P Modi","year":"2023","unstructured":"Modi, P., Shah, B. M. & Patel, S. Interleukin-1\u03b2 converting enzyme (ICE): a comprehensive review on discovery and development of caspase-1 inhibitors. Eur. J. Med. Chem. 261, 115861 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"2556_CR295","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1063-4584(03)00153-5","volume":"11","author":"K Rudolphi","year":"2003","unstructured":"Rudolphi, K. et al. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthr. Cartil. 11, 738\u2013746 (2003).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR296","first-page":"74","volume":"38","author":"W Huang","year":"2024","unstructured":"Huang, W., Tu, J., Qiao, A. & He, C. Effects of VX765 on osteoarthritis and chondrocyte inflammation in rats]. CJRRS 38, 74\u201381 (2024).","journal-title":"CJRRS"},{"key":"2556_CR297","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbi.2021.01.036","volume":"94","author":"C Dykstra-Aiello","year":"2021","unstructured":"Dykstra-Aiello, C. et al. A wake-like state in vitro induced by transmembrane TNF\/soluble TNF receptor reverse signaling. Brain Behav. Immun. 94, 245\u2013258 (2021).","journal-title":"Brain Behav. Immun."},{"key":"2556_CR298","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrd1175","volume":"2","author":"MA Palladino","year":"2003","unstructured":"Palladino, M. A., Bahjat, F. R., Theodorakis, E. A. & Moldawer, L. L. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2, 736\u2013746 (2003).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2556_CR299","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey, D. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244\u2013279 (2008).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR300","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","volume":"103","author":"MP Karampetsou","year":"2010","unstructured":"Karampetsou, M. P., Liossis, S. N. & Sfikakis, P. P. TNF-\u03b1 antagonists beyond approved indications: stories of success and prospects for the future. QJM 103, 917\u2013928 (2010).","journal-title":"QJM"},{"key":"2556_CR301","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11926-007-0066-2","volume":"9","author":"AR Erickson","year":"2007","unstructured":"Erickson, A. R. & Mikuls, T. R. Switching anti-TNF-alpha agents: what is the evidence?. Curr. Rheumatol. Rep. 9, 416\u2013420 (2007).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2556_CR302","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","volume":"49","author":"T Horiuchi","year":"2010","unstructured":"Horiuchi, T. et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 49, 1215\u20131228 (2010).","journal-title":"Rheumatology"},{"key":"2556_CR303","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2019.1586886","volume":"23","author":"J Medler","year":"2019","unstructured":"Medler, J. & Wajant, H. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opin. Ther. Targets 23, 295\u2013307 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2556_CR304","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41584-021-00639-6","volume":"17","author":"BL Salomon","year":"2021","unstructured":"Salomon, B. L. Insights into the biology and therapeutic implications of TNF and regulatory T cells. Nat. Rev. Rheumatol. 17, 487\u2013504 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR305","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fimmu.2018.00594","volume":"9","author":"H Zou","year":"2018","unstructured":"Zou, H. et al. Modulation of regulatory T cell activity by TNF receptor type II-targeting pharmacological agents. Front. Immunol. 9, 594 (2018).","journal-title":"Front. Immunol."},{"key":"2556_CR306","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cytogfr.2020.03.002","volume":"55","author":"N Zhang","year":"2020","unstructured":"Zhang, N., Wang, Z. & Zhao, Y. Selective inhibition of tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseases. Cytokine Growth Factor Rev. 55, 80\u201385 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2556_CR307","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1016\/j.biomaterials.2009.08.041","volume":"30","author":"H Shibata","year":"2009","unstructured":"Shibata, H. et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 30, 6638\u20136647 (2009).","journal-title":"Biomaterials"},{"key":"2556_CR308","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705485","volume":"12","author":"F Richter","year":"2021","unstructured":"Richter, F. et al. The TNFR1 antagonist atrosimab is therapeutic in mouse models of acute and chronic inflammation. Front. Immunol. 12, 705485 (2021).","journal-title":"Front. Immunol."},{"key":"2556_CR309","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","volume":"9","author":"OJ McElvaney","year":"2021","unstructured":"McElvaney, O. J., Curley, G. F., Rose-John, S. & McElvaney, N. G. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 9, 643\u2013654 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2556_CR310","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6 signaling in clinic. Immunity 50, 1007\u20131023 (2019).","journal-title":"Immunity"},{"key":"2556_CR311","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao, X. et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 141, 125\u2013139 (2014).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR312","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrrheum.2017.83","volume":"13","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S., Winthrop, K. & Calabrese, L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat. Rev. Rheumatol. 13, 399\u2013409 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR313","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John, S. et al. Targeting IL-6 trans-signalling: past, present and future prospects. Nat. Rev. Immunol. 23, 666\u2013681 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2556_CR314","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.782","volume":"102","author":"S Rose-John","year":"2017","unstructured":"Rose-John, S. The soluble interleukin 6 receptor: advanced therapeutic options in inflammation. Clin. Pharmacol. Ther. 102, 591\u2013598 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2556_CR315","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.joca.2024.02.006","volume":"32","author":"A Eitner","year":"2024","unstructured":"Eitner, A. et al. Importance of IL-6 trans-signaling and high autocrine IL-6 production in human osteoarthritic chondrocyte metabolism. Osteoarthr. Cartil. 32, 561\u2013573 (2024).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR316","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ajpath.2017.10.011","volume":"188","author":"K Prystaz","year":"2018","unstructured":"Prystaz, K. et al. Distinct effects of IL-6 classic and trans-signaling in bone fracture healing. Am. J. Pathol. 188, 474\u2013490 (2018).","journal-title":"Am. J. Pathol."},{"key":"2556_CR317","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2020-218547","volume":"80","author":"P Richette","year":"2021","unstructured":"Richette, P. et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann. Rheum. Dis. 80, 349\u2013355 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR318","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abc3480","volume":"14","author":"D Heise","year":"2021","unstructured":"Heise, D. et al. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T(H)17 cell expansion. Sci. Signal. 14, eabc3480 (2021).","journal-title":"Sci. Signal."},{"key":"2556_CR319","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","volume":"171","author":"MA Nowell","year":"2003","unstructured":"Nowell, M. A. et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J. Immunol. 171, 3202\u20133209 (2003).","journal-title":"J. Immunol."},{"key":"2556_CR320","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01690-y","volume":"22","author":"A Babendreyer","year":"2024","unstructured":"Babendreyer, A. et al. Downregulation of the metalloproteinases ADAM10 or ADAM17 promotes osteoclast differentiation. Cell Commun. Signal. 22, 322 (2024).","journal-title":"Cell Commun. Signal."},{"key":"2556_CR321","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","volume":"26","author":"F Schaper","year":"2015","unstructured":"Schaper, F. & Rose-John, S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26, 475\u2013487 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2556_CR322","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ajpath.2023.05.019","volume":"193","author":"C Cheng","year":"2023","unstructured":"Cheng, C. et al. miR-5581 contributes to osteoarthritis by targeting NRF1 to disturb the proliferation and functions of chondrocytes. Am. J. Pathol. 193, 1234\u20131247 (2023).","journal-title":"Am. J. Pathol."},{"key":"2556_CR323","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/BOR.0000000000000855","volume":"34","author":"M Fern\u00e1ndez-Moreno","year":"2022","unstructured":"Fern\u00e1ndez-Moreno, M., Rego-P\u00e9rez, I. & Blanco, F. J. Is osteoarthritis a mitochondrial disease? What is the evidence. Curr. Opin. Rheumatol. 34, 46\u201353 (2022).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2556_CR324","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1631\/jzus.B2300402","volume":"25","author":"H Cao","year":"2024","unstructured":"Cao, H. et al. Advances in the study of mitophagy in osteoarthritis. J. Zhejiang Univ. Sci. B 25, 197\u2013211 (2024).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"2556_CR325","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/nyas.12953","volume":"1371","author":"S Piao","year":"2016","unstructured":"Piao, S. & Amaravadi, R. K. Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci. 1371, 45\u201354 (2016).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2556_CR326","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar5078","volume":"360","author":"ML Skowyra","year":"2018","unstructured":"Skowyra, M. L., Schlesinger, P. H., Naismith, T. V. & Hanson, P. I. Triggered recruitment of ESCRT machinery promotes endolysosomal repair. Science 360, eaar5078 (2018).","journal-title":"Science"},{"key":"2556_CR327","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3390\/pharmaceutics15102464","volume":"15","author":"A Kozak","year":"2023","unstructured":"Kozak, A. et al. A new cathepsin D targeting drug delivery system based on immunoliposomes functionalized with lipidated pepstatin A. Pharmaceutics 15, 2464 (2023).","journal-title":"Pharmaceutics"},{"key":"2556_CR328","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116178","volume":"267","author":"F Terzani","year":"2024","unstructured":"Terzani, F. et al. Synthesis and biological evaluation of selective pepstatin based trifluoromethylated inhibitors of cathepsin D. Eur. J. Med. Chem. 267, 116178 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2556_CR329","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.joca.2009.03.015","volume":"17","author":"JR Connor","year":"2009","unstructured":"Connor, J. R. et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthr. Cartil. 17, 1236\u20131243 (2009).","journal-title":"Osteoarthr. Cartil."},{"key":"2556_CR330","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.joen.2015.04.013","volume":"41","author":"N Suzuki","year":"2015","unstructured":"Suzuki, N., Takimoto, K. & Kawashima, N. Cathepsin K inhibitor regulates inflammation and bone destruction in experimentally induced rat periapical lesions. J. Endod. 41, 1474\u20131479 (2015).","journal-title":"J. Endod."},{"key":"2556_CR331","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jmb.2019.08.010","volume":"432","author":"C Papadopoulos","year":"2020","unstructured":"Papadopoulos, C., Kravic, B. & Meyer, H. Repair or lysophagy: dealing with damaged lysosomes. J. Mol. Biol. 432, 231\u2013239 (2020).","journal-title":"J. Mol. Biol."},{"key":"2556_CR332","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1229","volume":"13","author":"Y Qing","year":"2023","unstructured":"Qing, Y. et al. Targeting lysosomal HSP70 induces acid sphingomyelinase-mediated disturbance of lipid metabolism and leads to cell death in T cell malignancies. Clin. Transl. Med. 13, e1229 (2023).","journal-title":"Clin. Transl. Med."},{"key":"2556_CR333","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1080\/15548627.2021.1995150","volume":"18","author":"T Tanaka","year":"2022","unstructured":"Tanaka, T. et al. LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization. Autophagy 18, 1629\u20131647 (2022).","journal-title":"Autophagy"},{"key":"2556_CR334","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/tra.12613","volume":"19","author":"F Wang","year":"2018","unstructured":"Wang, F., G\u00f3mez-Sintes, R. & Boya, P. Lysosomal membrane permeabilization and cell death. Traffic 19, 918\u2013931 (2018).","journal-title":"Traffic"},{"key":"2556_CR335","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41573-021-00320-3","volume":"21","author":"SJ Marciniak","year":"2022","unstructured":"Marciniak, S. J., Chambers, J. E. & Ron, D. Pharmacological targeting of endoplasmic reticulum stress in disease. Nat. Rev. Drug Discov. 21, 115\u2013140 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2556_CR336","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/ijms24021566","volume":"24","author":"G Bonsignore","year":"2023","unstructured":"Bonsignore, G., Martinotti, S. & Ranzato, E. Endoplasmic reticulum stress and cancer: could unfolded protein response be a druggable target for cancer therapy?. Int. J. Mol. Sci. 24, 1566 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR337","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.3390\/ijms21176127","volume":"21","author":"R Ghemrawi","year":"2020","unstructured":"Ghemrawi, R. & Khair, M. Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int. J. Mol. Sci. 21, 6127 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR338","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399407000361","volume":"9","author":"TW Loo","year":"2007","unstructured":"Loo, T. W. & Clarke, D. M. Chemical and pharmacological chaperones as new therapeutic agents. Expert Rev. Mol. Med. 9, 1\u201318 (2007).","journal-title":"Expert Rev. Mol. Med."},{"issue":"Suppl 2","key":"2556_CR339","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1463-1326.2010.01282.x","volume":"12","author":"F Engin","year":"2010","unstructured":"Engin, F. & Hotamisligil, G. S. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diab. Obes. Metab. 12(Suppl 2), 108\u2013115 (2010).","journal-title":"Diab. Obes. Metab."},{"key":"2556_CR340","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/jbmr.4176","volume":"36","author":"K Li","year":"2021","unstructured":"Li, K. et al. DEPTOR prevents osteoarthritis development via interplay with TRC8 to reduce endoplasmic reticulum stress in chondrocytes. J. Bone Miner. Res. 36, 400\u2013411 (2021).","journal-title":"J. Bone Miner. Res."},{"key":"2556_CR341","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3892\/ijmm.2015.2295","volume":"36","author":"C Liu","year":"2015","unstructured":"Liu, C. et al. Tauroursodeoxycholic acid suppresses endoplasmic reticulum stress in the chondrocytes of patients with osteoarthritis. Int. J. Mol. Med. 36, 1081\u20131087 (2015).","journal-title":"Int. J. Mol. Med."},{"key":"2556_CR342","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.3390\/molecules25143145","volume":"25","author":"ML Tran","year":"2020","unstructured":"Tran, M. L., G\u00e9nisson, Y., Ballereau, S. & Dehoux, C. Second-generation pharmacological chaperones: beyond inhibitors. Molecules 25, 3145 (2020).","journal-title":"Molecules"},{"key":"2556_CR343","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.3390\/ijms24065819","volume":"24","author":"D Grasso","year":"2023","unstructured":"Grasso, D., Galderisi, S., Santucci, A. & Bernini, A. Pharmacological chaperones and protein conformational diseases: approaches of computational structural biology. Int. J. Mol. Sci. 24, 5819 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2556_CR344","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1742-4658.2006.05181.x","volume":"273","author":"TK Chaudhuri","year":"2006","unstructured":"Chaudhuri, T. K. & Paul, S. Protein-misfolding diseases and chaperone-based therapeutic approaches. FEBS J. 273, 1331\u20131349 (2006).","journal-title":"FEBS J."},{"key":"2556_CR345","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-biochem-060208-092442","volume":"82","author":"YE Kim","year":"2013","unstructured":"Kim, Y. E. et al. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 82, 323\u2013355 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"2556_CR346","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pharmthera.2015.07.003","volume":"154","author":"JD Ramsey","year":"2015","unstructured":"Ramsey, J. D. & Flynn, N. H. Cell-penetrating peptides transport therapeutics into cells. Pharmacol. Ther. 154, 78\u201386 (2015).","journal-title":"Pharmacol. Ther."},{"key":"2556_CR347","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.apcsb.2018.01.004","volume":"112","author":"Y He","year":"2018","unstructured":"He, Y., Li, F. & Huang, Y. Smart cell-penetrating peptide-based techniques for intracellular delivery of therapeutic macromolecules. Adv. Protein Chem. Struct. Biol. 112, 183\u2013220 (2018).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"2556_CR348","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425247.5.1.105","volume":"5","author":"C Foged","year":"2008","unstructured":"Foged, C. & Nielsen, H. M. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin. Drug Deliv. 5, 105\u2013117 (2008).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2556_CR349","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/164_2023_650","volume":"284","author":"Y Yamada","year":"2024","unstructured":"Yamada, Y. & Harashima, H. RNA delivery to mitochondria. Handb. Exp. Pharmacol. 284, 329\u2013339 (2024).","journal-title":"Handb. Exp. Pharmacol."},{"key":"2556_CR350","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.7150\/thno.35748","volume":"9","author":"H Yu","year":"2019","unstructured":"Yu, H. et al. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy. Theranostics 9, 7033\u20137050 (2019).","journal-title":"Theranostics"},{"key":"2556_CR351","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1021\/acs.accounts.6b00277","volume":"49","author":"SR Jean","year":"2016","unstructured":"Jean, S. R. et al. Peptide-mediated delivery of chemical probes and therapeutics to mitochondria. Acc. Chem. Res. 49, 1893\u20131902 (2016).","journal-title":"Acc. Chem. Res."},{"key":"2556_CR352","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1021\/acsnano.1c09456","volume":"16","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Zhang, J., Tu, Y. & Zhu, L. Potential-independent intracellular drug delivery and mitochondrial targeting. ACS Nano 16, 1409\u20131420 (2022).","journal-title":"ACS Nano"},{"key":"2556_CR353","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.addr.2020.09.010","volume":"154-155","author":"Y Yamada","year":"2020","unstructured":"Yamada, Y. et al. Power of mitochondrial drug delivery systems to produce innovative nanomedicines. Adv. Drug Deliv. Rev. 154-155, 187\u2013209 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2556_CR354","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2015.10.023","volume":"240","author":"P Lu","year":"2016","unstructured":"Lu, P., Bruno, B. J., Rabenau, M. & Lim, C. S. Delivery of drugs and macromolecules to the mitochondria for cancer therapy. J. Control. Release 240, 38\u201351 (2016).","journal-title":"J. Control. Release"},{"key":"2556_CR355","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124397","volume":"661","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. Construction of mitochondrial-targeting nano-prodrug for enhanced Rhein delivery and treatment for osteoarthritis in vitro. Int. J. Pharm. 661, 124397 (2024).","journal-title":"Int. J. Pharm."},{"key":"2556_CR356","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.1002\/anie.201901699","volume":"58","author":"P Yuan","year":"2019","unstructured":"Yuan, P. et al. Mitochondria-targeting, intracellular delivery of native proteins using biodegradable silica nanoparticles. Angew. Chem. Int. Ed. Engl. 58, 7657\u20137661 (2019).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2556_CR357","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202302037","volume":"222","author":"H Wu","year":"2023","unstructured":"Wu, H. et al. C17orf80 binds the mitochondrial genome to promote its replication. J. Cell Biol. 222, e202302037 (2023).","journal-title":"J. Cell Biol."},{"key":"2556_CR358","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.15252\/embj.201592994","volume":"35","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y., Chen, Y., Gucek, M. & Xu, H. The mitochondrial outer membrane protein MDI promotes local protein synthesis and mtDNA replication. EMBO J. 35, 1045\u20131057 (2016).","journal-title":"EMBO J."},{"key":"2556_CR359","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12951-019-0451-9","volume":"17","author":"CX Zhang","year":"2019","unstructured":"Zhang, C. X. et al. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J. Nanobiotechnol. 17, 18 (2019).","journal-title":"J. Nanobiotechnol."},{"key":"2556_CR360","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05369-5","volume":"13","author":"NK Liu","year":"2022","unstructured":"Liu, N. K. et al. Restoring mitochondrial cardiolipin homeostasis reduces cell death and promotes recovery after spinal cord injury. Cell Death Dis. 13, 1058 (2022).","journal-title":"Cell Death Dis."},{"key":"2556_CR361","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1080\/10717544.2017.1402220","volume":"24","author":"X Kuang","year":"2017","unstructured":"Kuang, X. et al. SS-31 peptide enables mitochondrial targeting drug delivery: a promising therapeutic alteration to prevent hair cell damage from aminoglycosides. Drug Deliv. 24, 1750\u20131761 (2017).","journal-title":"Drug Deliv."},{"key":"2556_CR362","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/biom10071008","volume":"10","author":"P Horten","year":"2020","unstructured":"Horten, P., Colina-Tenorio, L. & Rampelt, H. Biogenesis of mitochondrial metabolite carriers. Biomolecules 10, 1008 (2020).","journal-title":"Biomolecules"},{"key":"2556_CR363","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.molcel.2023.02.020","volume":"83","author":"JD Busch","year":"2023","unstructured":"Busch, J. D., Fielden, L. F., Pfanner, N. & Wiedemann, N. Mitochondrial protein transport: versatility of translocases and mechanisms. Mol. Cell. 83, 890\u2013910 (2023).","journal-title":"Mol. Cell."},{"key":"2556_CR364","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/acsbiomaterials.1c01114","volume":"8","author":"N Yoshinaga","year":"2022","unstructured":"Yoshinaga, N. & Numata, K. Rational designs at the forefront of mitochondria-targeted gene delivery: recent progress and future perspectives. ACS Biomater. Sci. Eng. 8, 348\u2013359 (2022).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2556_CR365","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40280-3","volume":"14","author":"Y Zou","year":"2023","unstructured":"Zou, Y. et al. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment. Nat. Commun. 14, 4557 (2023).","journal-title":"Nat. Commun."},{"key":"2556_CR366","doi-asserted-by":"publisher","first-page":"E9863","DOI":"10.1073\/pnas.1708782114","volume":"114","author":"X Huang","year":"2017","unstructured":"Huang, X. et al. Sequences flanking the transmembrane segments facilitate mitochondrial localization and membrane fusion by mitofusin. Proc. Natl. Acad. Sci. USA 114, E9863\u2013e9872 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2556_CR367","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh9751","volume":"16","author":"R Deng","year":"2024","unstructured":"Deng, R. et al. Chondrocyte membrane-coated nanoparticles promote drug retention and halt cartilage damage in rat and canine osteoarthritis. Sci. Transl. Med. 16, eadh9751 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2556_CR368","doi-asserted-by":"publisher","first-page":"114828","DOI":"10.1016\/j.addr.2023.114828","volume":"197","author":"M Uzhytchak","year":"2023","unstructured":"Uzhytchak, M. et al. Lysosomal nanotoxicity: impact of nanomedicines on lysosomal function. Adv. Drug Deliv. Rev. 197, 114828 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2556_CR369","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1080\/15548627.2022.2125629","volume":"19","author":"M Hu","year":"2023","unstructured":"Hu, M., Chen, J., Liu, S. & Xu, H. The acid gate in the lysosome. Autophagy 19, 1368\u20131370 (2023).","journal-title":"Autophagy"},{"key":"2556_CR370","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1002\/smll.201503709","volume":"12","author":"YX Lin","year":"2016","unstructured":"Lin, Y. X. et al. pH-sensitive polymeric nanoparticles modulate autophagic effect via lysosome impairment. Small 12, 2921\u20132931 (2016).","journal-title":"Small"},{"issue":"Pt 3","key":"2556_CR371","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1242\/jcs.113.3.377","volume":"113","author":"HK V\u00e4\u00e4n\u00e4nen","year":"2000","unstructured":"V\u00e4\u00e4n\u00e4nen, H. K., Zhao, H., Mulari, M. & Halleen, J. M. The cell biology of osteoclast function. J. Cell Sci. 113(Pt 3), 377\u2013381 (2000).","journal-title":"J. Cell Sci."},{"key":"2556_CR372","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38165-6","volume":"14","author":"J Zeng","year":"2023","unstructured":"Zeng, J. et al. Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease. Nat. Commun. 14, 2573 (2023).","journal-title":"Nat. Commun."},{"key":"2556_CR373","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1080\/15548627.2022.2108252","volume":"19","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis. Autophagy 19, 886\u2013903 (2023).","journal-title":"Autophagy"},{"key":"2556_CR374","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1042\/BST0381479","volume":"38","author":"NH Petersen","year":"2010","unstructured":"Petersen, N. H. & Kirkegaard, T. HSP70 and lysosomal storage disorders: novel therapeutic opportunities. Biochem. Soc. Trans. 38, 1479\u20131483 (2010).","journal-title":"Biochem. Soc. Trans."},{"key":"2556_CR375","doi-asserted-by":"publisher","first-page":"355ra118","DOI":"10.1126\/scitranslmed.aad9823","volume":"8","author":"T Kirkegaard","year":"2016","unstructured":"Kirkegaard, T. et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci. Transl. Med. 8, 355ra118 (2016).","journal-title":"Sci. Transl. Med."},{"key":"2556_CR376","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature08710","volume":"463","author":"T Kirkegaard","year":"2010","unstructured":"Kirkegaard, T. et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463, 549\u2013553 (2010).","journal-title":"Nature"},{"key":"2556_CR377","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41392-021-00778-y","volume":"6","author":"M Cao","year":"2021","unstructured":"Cao, M., Luo, X., Wu, K. & He, X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct. Target. Ther. 6, 379 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2556_CR378","doi-asserted-by":"publisher","first-page":"112046","DOI":"10.1016\/j.colsurfb.2021.112046","volume":"208","author":"L Qiao","year":"2021","unstructured":"Qiao, L. et al. Research on endoplasmic reticulum-targeting fluorescent probes and endoplasmic reticulum stress-mediated nanoanticancer strategies: a review. Colloids Surf. B. 208, 112046 (2021).","journal-title":"Colloids Surf. B."},{"key":"2556_CR379","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2020.11.054","volume":"329","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application. J. Control. Release 329, 337\u2013352 (2021).","journal-title":"J. Control. Release"},{"key":"2556_CR380","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1021\/acs.jmedchem.7b01907","volume":"61","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy. J. Med. Chem. 61, 3952\u20133961 (2018).","journal-title":"J. Med. Chem."},{"key":"2556_CR381","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201909268","volume":"30","author":"P Alam","year":"2020","unstructured":"Alam, P. et al. Red AIE-active fluorescent probes with tunable organelle-specific targeting. Adv. Funct. Mater. 30, 1909268 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"2556_CR382","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1021\/acsami.3c14068","volume":"16","author":"Z Miao","year":"2024","unstructured":"Miao, Z. et al. Endoplasmic reticulum-targeting AIE photosensitizers to boost immunogenic cell death for immunotherapy of bladder carcinoma. ACS Appl. Mater. Interfaces 16, 245\u2013260 (2024).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2556_CR383","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bbrc.2007.08.112","volume":"362","author":"K Matsuo","year":"2007","unstructured":"Matsuo, K. et al. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Biochem. Biophys. Res. Commun. 362, 1069\u20131072 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2556_CR384","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1016\/j.biomaterials.2014.01.032","volume":"35","author":"CH Ting","year":"2014","unstructured":"Ting, C. H. et al. The mechanisms by which pardaxin, a natural cationic antimicrobial peptide, targets the endoplasmic reticulum and induces c-FOS. Biomaterials 35, 3627\u20133640 (2014).","journal-title":"Biomaterials"},{"key":"2556_CR385","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.4049\/jimmunol.1801599","volume":"202","author":"CL Yen","year":"2019","unstructured":"Yen, C. L. et al. Targeted delivery of curcumin rescues endoplasmic reticulum-retained mutant NOX2 protein and avoids leukocyte apoptosis. J. Immunol. 202, 3394\u20133403 (2019).","journal-title":"J. Immunol."},{"key":"2556_CR386","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","volume":"305","author":"F Zahednezhad","year":"2019","unstructured":"Zahednezhad, F. et al. Liposome and immune system interplay: challenges and potentials. J. Control. Release 305, 194\u2013209 (2019).","journal-title":"J. Control. Release"},{"key":"2556_CR387","doi-asserted-by":"publisher","first-page":"5672","DOI":"10.3390\/molecules25235672","volume":"25","author":"B Almeida","year":"2020","unstructured":"Almeida, B., Nag, O. K., Rogers, K. E. & Delehanty, J. B. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules 25, 5672 (2020).","journal-title":"Molecules"},{"key":"2556_CR388","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1096\/fj.09-145755","volume":"24","author":"S Pollock","year":"2010","unstructured":"Pollock, S. et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 24, 1866\u20131878 (2010).","journal-title":"FASEB J."},{"key":"2556_CR389","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1021\/acscentsci.9b01052","volume":"6","author":"X Yuan","year":"2020","unstructured":"Yuan, X. et al. Virus-like nonvirus cationic liposome for efficient gene delivery via endoplasmic reticulum pathway. ACS Cent. Sci. 6, 174\u2013188 (2020).","journal-title":"ACS Cent. Sci."},{"key":"2556_CR390","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf0988","volume":"9","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Urchin-like ceria nanoparticles for enhanced gene therapy of osteoarthritis. Sci. Adv. 9, eadf0988 (2023).","journal-title":"Sci. Adv."},{"key":"2556_CR391","doi-asserted-by":"publisher","first-page":"18249","DOI":"10.1039\/D0NR03156A","volume":"12","author":"B Qin","year":"2020","unstructured":"Qin, B. et al. Targeting DNA to the endoplasmic reticulum efficiently enhances gene delivery and therapy. Nanoscale 12, 18249\u201318262 (2020).","journal-title":"Nanoscale"},{"key":"2556_CR392","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1021\/mp200583d","volume":"9","author":"MJ Reilly","year":"2012","unstructured":"Reilly, M. J., Larsen, J. D. & Sullivan, M. O. Polyplexes traffic through caveolae to the Golgi and endoplasmic reticulum en route to the nucleus. Mol. Pharm. 9, 1280\u20131290 (2012).","journal-title":"Mol. Pharm."},{"key":"2556_CR393","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jconrel.2021.11.046","volume":"341","author":"LY Qi","year":"2022","unstructured":"Qi, L. Y. et al. Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway. J. Control. Release 341, 511\u2013523 (2022).","journal-title":"J. Control. Release"},{"key":"2556_CR394","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.actbio.2021.03.062","volume":"133","author":"M Klimak","year":"2021","unstructured":"Klimak, M. et al. Immunoengineering the next generation of arthritis therapies. Acta Biomater. 133, 74\u201386 (2021).","journal-title":"Acta Biomater."},{"key":"2556_CR395","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41584-025-01223-y","volume":"21","author":"D Moulin","year":"2025","unstructured":"Moulin, D. et al. The role of the immune system in osteoarthritis: mechanisms, challenges and future directions. Nat. Rev. Rheumatol. 21, 221\u2013236 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR396","doi-asserted-by":"publisher","first-page":"101684","DOI":"10.1016\/j.arr.2022.101684","volume":"80","author":"H Yu","year":"2022","unstructured":"Yu, H., Huang, Y. & Yang, L. Research progress in the use of mesenchymal stem cells and their derived exosomes in the treatment of osteoarthritis. Ageing Res. Rev. 80, 101684 (2022).","journal-title":"Ageing Res. Rev."},{"key":"2556_CR397","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/rheumatology\/keaa745","volume":"60","author":"M Alahdal","year":"2021","unstructured":"Alahdal, M. et al. Potential efficacy of dendritic cell immunomodulation in the treatment of osteoarthritis. Rheumatology 60, 507\u2013517 (2021).","journal-title":"Rheumatology"},{"key":"2556_CR398","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.biomaterials.2018.07.011","volume":"180","author":"M Dai","year":"2018","unstructured":"Dai, M. et al. Cartilage repair in degenerative osteoarthritis mediated by squid type II collagen via immunomodulating activation of M2 macrophages, inhibiting apoptosis and hypertrophy of chondrocytes. Biomaterials 180, 91\u2013103 (2018).","journal-title":"Biomaterials"},{"key":"2556_CR399","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054938","volume":"13","author":"C Liang","year":"2022","unstructured":"Liang, C. et al. Engineered M2a macrophages for the treatment of osteoarthritis. Front. Immunol. 13, 1054938 (2022).","journal-title":"Front. Immunol."},{"key":"2556_CR400","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41584-023-00906-8","volume":"19","author":"J McHugh","year":"2023","unstructured":"McHugh, J. T(reg) cell-inducing nanoparticles show promise for treating OA. Nat. Rev. Rheumatol. 19, 62 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2556_CR401","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5284","volume":"8","author":"HS Sohn","year":"2022","unstructured":"Sohn, H. S. et al. Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis. Sci. Adv. 8, eabo5284 (2022).","journal-title":"Sci. Adv."},{"key":"2556_CR402","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.731756","volume":"13","author":"S Xian Bo","year":"2022","unstructured":"Xian Bo, S. et al. The research progress of exosomes in osteoarthritis, with particular emphasis on the therapeutic effect. Front. Pharmacol. 13, 731756 (2022).","journal-title":"Front. Pharmacol."},{"key":"2556_CR403","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.7150\/ijbs.41637","volume":"16","author":"Q Zhou","year":"2020","unstructured":"Zhou, Q., Cai, Y., Jiang, Y. & Lin, X. Exosomes in osteoarthritis and cartilage injury: advanced development and potential therapeutic strategies. Int. J. Biol. Sci. 16, 1811\u20131820 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"2556_CR404","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202403199","volume":"36","author":"Y Xia","year":"2024","unstructured":"Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, e2403199 (2024).","journal-title":"Adv. Mater."},{"key":"2556_CR405","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41368-022-00187-z","volume":"14","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Exosomes rewire the cartilage microenvironment in osteoarthritis: from intercellular communication to therapeutic strategies. Int. J. Oral. Sci. 14, 40 (2022).","journal-title":"Int. J. Oral. Sci."},{"key":"2556_CR406","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CM9.0000000000003325","volume":"138","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Mechanism of osteoarthritis treatment by exosomes. Chin. Med. J. 138, 367\u2013369 (2025).","journal-title":"Chin. Med. J."},{"key":"2556_CR407","doi-asserted-by":"publisher","first-page":"123365","DOI":"10.1016\/j.lfs.2024.123365","volume":"362","author":"HM Okuyan","year":"2025","unstructured":"Okuyan, H. M., Co\u015fkun, A. & Begen, M. A. Current status, opportunities, and challenges of exosomes in diagnosis and treatment of osteoarthritis. Life Sci. 362, 123365 (2025).","journal-title":"Life Sci."},{"key":"2556_CR408","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41413-020-0100-9","volume":"8","author":"Z Ni","year":"2020","unstructured":"Ni, Z. et al. Exosomes: roles and therapeutic potential in osteoarthritis. Bone Res. 8, 25 (2020).","journal-title":"Bone Res."},{"key":"2556_CR409","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/scrt116","volume":"3","author":"PK Gupta","year":"2012","unstructured":"Gupta, P. K., Das, A. K., Chullikana, A. & Majumdar, A. S. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res. Ther. 3, 25 (2012).","journal-title":"Stem Cell Res. Ther."},{"key":"2556_CR410","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406428","volume":"11","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. USP26 combats age-related declines in self-renewal and multipotent differentiation of BMSC by maintaining mitochondrial homeostasis. Adv. Sci. 11, e2406428 (2024).","journal-title":"Adv. Sci."},{"key":"2556_CR411","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/rheumatology\/keaa051","volume":"59","author":"S Asghar","year":"2020","unstructured":"Asghar, S. et al. Exosomes in intercellular communication and implications for osteoarthritis. Rheumatology 59, 57\u201368 (2020).","journal-title":"Rheumatology"},{"key":"2556_CR412","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","volume":"159","author":"OM Elsharkasy","year":"2020","unstructured":"Elsharkasy, O. M. et al. Extracellular vesicles as drug delivery systems: why and how?. Adv. Drug Deliv. Rev. 159, 332\u2013343 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2556_CR413","volume":"18","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Therapeutic potential of exosome-based personalized delivery platform in chronic inflammatory diseases. Asian J. Pharm. Sci. 18, 100772 (2023).","journal-title":"Asian J. Pharm. Sci."},{"key":"2556_CR414","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41565-024-01774-3","volume":"20","author":"RP Carney","year":"2025","unstructured":"Carney, R. P. et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat. Nanotechnol. 20, 14\u201325 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"2556_CR415","doi-asserted-by":"publisher","first-page":"19174","DOI":"10.1039\/D4NR02792B","volume":"16","author":"A Selvadoss","year":"2024","unstructured":"Selvadoss, A., Baby, H. M., Zhang, H. & Bajpayee, A. G. Harnessing exosomes for advanced osteoarthritis therapy. Nanoscale 16, 19174\u201319191 (2024).","journal-title":"Nanoscale"},{"key":"2556_CR416","doi-asserted-by":"publisher","first-page":"36938","DOI":"10.1021\/acsami.0c10458","volume":"12","author":"Y Liang","year":"2020","unstructured":"Liang, Y. et al. Chondrocyte-targeted microRNA delivery by engineered exosomes toward a cell-free osteoarthritis therapy. ACS Appl. Mater. Interfaces 12, 36938\u201336947 (2020).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2556_CR417","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120539","volume":"269","author":"X Xu","year":"2021","unstructured":"Xu, X. et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials 269, 120539 (2021).","journal-title":"Biomaterials"},{"key":"2556_CR418","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202301443","volume":"8","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. Charge-reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment. Small Methods 8, e2301443 (2024).","journal-title":"Small Methods"},{"key":"2556_CR419","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1124\/jpet.107.125674","volume":"323","author":"NR Gavva","year":"2007","unstructured":"Gavva, N. R. et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther. 323, 128\u2013137 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2556_CR420","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2174\/156802611796904898","volume":"11","author":"SR Eid","year":"2011","unstructured":"Eid, S. R. Therapeutic targeting of TRP channels-the TR(i)P to pain relief. Curr. Top. Med. Chem. 11, 2118\u20132130 (2011).","journal-title":"Curr. Top. Med. Chem."},{"key":"2556_CR421","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/14728222.2024.2416961","volume":"28","author":"A Mobasheri","year":"2024","unstructured":"Mobasheri, A., Rannou, F., Ivanavicius, S. & Conaghan, P. G. Targeting the TRPV1 pain pathway in osteoarthritis of the knee. Expert Opin. Ther. Targets 28, 843\u2013856 (2024).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2556_CR422","doi-asserted-by":"publisher","first-page":"39663","DOI":"10.1074\/jbc.M111.273581","volume":"286","author":"M Papakosta","year":"2011","unstructured":"Papakosta, M. et al. The chimeric approach reveals that differences in the TRPV1 pore domain determine species-specific sensitivity to block of heat activation. J. Biol. Chem. 286, 39663\u201339672 (2011).","journal-title":"J. Biol. Chem."},{"key":"2556_CR423","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/molecules26040778","volume":"26","author":"JN Campbell","year":"2021","unstructured":"Campbell, J. N. et al. Injectable capsaicin for the management of pain due to osteoarthritis. Molecules 26, 778 (2021).","journal-title":"Molecules"},{"key":"2556_CR424","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1097\/j.pain.0000000000001314","volume":"159","author":"MJ Iadarola","year":"2018","unstructured":"Iadarola, M. J. et al. Long-term pain relief in canine osteoarthritis by a single intra-articular injection of resiniferatoxin, a potent TRPV1 agonist. Pain 159, 2105\u20132114 (2018).","journal-title":"Pain"},{"key":"2556_CR425","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40360-016-0074-9","volume":"17","author":"M Alsalem","year":"2016","unstructured":"Alsalem, M. et al. Anti-nociceptive and desensitizing effects of olvanil on capsaicin-induced thermal hyperalgesia in the rat. BMC Pharmacol. Toxicol. 17, 31 (2016).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"2556_CR426","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-4-48","volume":"4","author":"SR Eid","year":"2008","unstructured":"Eid, S. R. et al. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain. 4, 48 (2008).","journal-title":"Mol. Pain."},{"key":"2556_CR427","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-3-40","volume":"3","author":"M Petrus","year":"2007","unstructured":"Petrus, M. et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol. Pain. 3, 40 (2007).","journal-title":"Mol. Pain."},{"key":"2556_CR428","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bmcl.2009.10.113","volume":"20","author":"J Defalco","year":"2010","unstructured":"Defalco, J. et al. Oxime derivatives related to AP18: agonists and antagonists of the TRPA1 receptor. Bioorg. Med. Chem. Lett. 20, 276\u2013279 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2556_CR429","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3390\/md21120617","volume":"21","author":"EE Maleeva","year":"2023","unstructured":"Maleeva, E. E. et al. Potentiating TRPA1 by sea anemone peptide Ms 9a-1 reduces pain and inflammation in a model of osteoarthritis. Mar. Drugs 21, 617 (2023).","journal-title":"Mar. Drugs"},{"key":"2556_CR430","doi-asserted-by":"publisher","first-page":"113321","DOI":"10.1016\/j.intimp.2024.113321","volume":"143","author":"S Lu","year":"2024","unstructured":"Lu, S. & Fang, C. Isosakuranetin inhibits subchondral osteoclastogenesis for attenuating osteoarthritis via suppressing NF-\u03baB\/CXCL2 axis. Int. Immunopharmacol. 143, 113321 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"2556_CR431","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s43440-020-00207-x","volume":"73","author":"H Wei","year":"2021","unstructured":"Wei, H., Chen, Z., Koivisto, A. & Pertovaara, A. Spinal mechanisms contributing to the development of pain hypersensitivity induced by sphingolipids in the rat. Pharmacol. Rep. 73, 672\u2013679 (2021).","journal-title":"Pharmacol. Rep."},{"key":"2556_CR432","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/j.pain.0000000000000846","volume":"158","author":"U Kr\u00fcgel","year":"2017","unstructured":"Kr\u00fcgel, U., Straub, I., Beckmann, H. & Schaefer, M. Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. Pain 158, 856\u2013867 (2017).","journal-title":"Pain"},{"key":"2556_CR433","first-page":"109","volume":"36","author":"HE Eker","year":"2017","unstructured":"Eker, H. E., Cok, O. Y., Aribogan, A. & Arslan, G. The efficacy of intra-articular lidocaine administration in chronic knee pain due to osteoarthritis: a randomized, double-blind, controlled study. Anaesth. Crit. Care Pain. Med. 36, 109\u2013114 (2017).","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"2556_CR434","doi-asserted-by":"publisher","first-page":"E573","DOI":"10.36076\/ppj.2018.5.E573","volume":"21","author":"A Romman","year":"2018","unstructured":"Romman, A., Salama-Hanna, J. & Dwivedi, S. Mexiletine usage in a chronic pain clinic: indications, tolerability, and side effects. Pain. Physician 21, E573\u2013e579 (2018).","journal-title":"Pain. Physician"},{"key":"2556_CR435","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1213\/00000539-200210000-00036","volume":"95","author":"A Fassoulaki","year":"2002","unstructured":"Fassoulaki, A., Patris, K., Sarantopoulos, C. & Hogan, Q. The analgesic effect of gabapentin and mexiletine after breast surgery for cancer. Anesth. Analg. 95, 985\u2013991 (2002).","journal-title":"Anesth. Analg."},{"issue":"Suppl 3","key":"2556_CR436","first-page":"S64","volume":"28","author":"JM Pellock","year":"1987","unstructured":"Pellock, J. M. Carbamazepine side effects in children and adults. Epilepsia 28(Suppl 3), S64\u2013S70 (1987).","journal-title":"Epilepsia"},{"key":"2556_CR437","doi-asserted-by":"publisher","first-page":"602","DOI":"10.5312\/wjo.v15.i6.602","volume":"15","author":"R Vaid","year":"2024","unstructured":"Vaid, R., Sohail, A. & Amir, N. Carbamazepine in osteoarthritis treatment: a novel approach targeting Nav1.7 channels. World J. Orthop. 15, 602\u2013604 (2024).","journal-title":"World J. Orthop."},{"key":"2556_CR438","doi-asserted-by":"publisher","first-page":"m4825","DOI":"10.1136\/bmj.m4825","volume":"372","author":"GE Ferreira","year":"2021","unstructured":"Ferreira, G. E. et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ 372, m4825 (2021).","journal-title":"BMJ"},{"key":"2556_CR439","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/toxins8030078","volume":"8","author":"JR Deuis","year":"2016","unstructured":"Deuis, J. R. et al. Analgesic effects of GpTx-1, PF-04856264 and CNV1014802 in a mouse model of NaV1.7-mediated pain. Toxins 8, 78 (2016).","journal-title":"Toxins"},{"key":"2556_CR440","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1097\/j.pain.0000000000001567","volume":"160","author":"A Mueller","year":"2019","unstructured":"Mueller, A. et al. Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen. Pain 160, 1766\u20131780 (2019).","journal-title":"Pain"},{"key":"2556_CR441","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1073\/pnas.0611364104","volume":"104","author":"MF Jarvis","year":"2007","unstructured":"Jarvis, M. F. et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl. Acad. Sci. USA 104, 8520\u20138525 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2556_CR442","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-025-08402-8","volume":"26","author":"SJ DiMartino","year":"2025","unstructured":"DiMartino, S. J. et al. Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip. BMC Musculoskelet. Disord. 26, 192 (2025).","journal-title":"BMC Musculoskelet. Disord."},{"key":"2556_CR443","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","volume":"35","author":"KM Kelly","year":"2019","unstructured":"Kelly, K. M. et al. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. Curr. Med. Res. Opin. 35, 2117\u20132127 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"2556_CR444","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ab.2015.09.019","volume":"493","author":"KS Sheffield","year":"2016","unstructured":"Sheffield, K. S., Kennedy, A. E., Scott, J. A. & Ross, G. M. Characterizing nerve growth factor-p75(NTR) interactions and small molecule inhibition using surface plasmon resonance spectroscopy. Anal. Biochem. 493, 21\u201326 (2016).","journal-title":"Anal. Biochem."},{"key":"2556_CR445","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1124\/jpet.109.159079","volume":"332","author":"JK Eibl","year":"2010","unstructured":"Eibl, J. K., Chapelsky, S. A. & Ross, G. M. Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J. Pharmacol. Exp. Ther. 332, 446\u2013454 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2556_CR446","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T. & Saari, T. I. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin. Pharmacokinet. 55, 1059\u20131077 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"2556_CR447","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/SPC.0b013e328352812c","volume":"6","author":"RF Bell","year":"2012","unstructured":"Bell, R. F. Ketamine for chronic noncancer pain: concerns regarding toxicity. Curr. Opin. Support Pa. 6, 183\u2013187 (2012).","journal-title":"Curr. Opin. Support Pa."},{"key":"2556_CR448","first-page":"204","volume":"48","author":"Q Cheng","year":"2024","unstructured":"Cheng, Q. et al. Memantine attenuates the development of osteoarthritis by blocking NMDA receptor mediated calcium overload and chondrocyte senescence. J. Orthop. Transl. 48, 204\u2013216 (2024).","journal-title":"J. Orthop. Transl."},{"key":"2556_CR449","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.rvsc.2021.03.003","volume":"136","author":"Z Huang","year":"2021","unstructured":"Huang, Z. et al. MK801 regulates the expression of key osteoarthritis factors in osteoarthritis synovial fibroblasts through complement C5. Res. Vet. Sci. 136, 377\u2013384 (2021).","journal-title":"Res. Vet. Sci."},{"key":"2556_CR450","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/ph17050639","volume":"17","author":"AO Egunlusi","year":"2024","unstructured":"Egunlusi, A. O. & Joubert, J. NMDA receptor antagonists: emerging insights into molecular mechanisms and clinical applications in neurological disorders. Pharmaceuticals 17, 639 (2024).","journal-title":"Pharmaceuticals"},{"key":"2556_CR451","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0028-3908(98)00218-4","volume":"38","author":"S Boyce","year":"1999","unstructured":"Boyce, S. et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38, 611\u2013623 (1999).","journal-title":"Neuropharmacology"},{"key":"2556_CR452","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003495-200059010-00004","volume":"59","author":"GJ Lees","year":"2000","unstructured":"Lees, G. J. Pharmacology of AMPA\/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 59, 33\u201378 (2000).","journal-title":"Drugs"},{"key":"2556_CR453","doi-asserted-by":"publisher","first-page":"580","DOI":"10.7326\/M20-4938","volume":"173","author":"N Lane","year":"2020","unstructured":"Lane, N. & Felson, D. A promising treatment for osteoarthritis?. Ann. Intern. Med. 173, 580\u2013581 (2020).","journal-title":"Ann. Intern. Med."},{"key":"2556_CR454","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell, D. J. et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 65, 2486\u20132496 (2013).","journal-title":"Arthritis Rheum."},{"key":"2556_CR455","doi-asserted-by":"publisher","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","volume":"13","author":"DD Arnold","year":"2022","unstructured":"Arnold, D. D., Yalamanoglu, A. & Boyman, O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front. Immunol. 13, 888392 (2022).","journal-title":"Front. Immunol."},{"key":"2556_CR456","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","volume":"78","author":"M Kloppenburg","year":"2019","unstructured":"Kloppenburg, M. et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann. Rheum. Dis. 78, 413\u2013420 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR457","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00296-009-0872-0","volume":"29","author":"A Fioravanti","year":"2009","unstructured":"Fioravanti, A., Fabbroni, M., Cerase, A. & Galeazzi, M. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol. Int. 29, 961\u2013965 (2009).","journal-title":"Rheumatol. Int."},{"key":"2556_CR458","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/03008207.2012.661001","volume":"53","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Efficacy of infliximab in a rabbit model of osteoarthritis. Connect. Tissue Res. 53, 355\u2013358 (2012).","journal-title":"Connect. Tissue Res."},{"key":"2556_CR459","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1136\/annrheumdis-2018-213202","volume":"77","author":"M Kloppenburg","year":"2018","unstructured":"Kloppenburg, M. et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 77, 1757\u20131764 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR460","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/annrheumdis-2014-205348","volume":"74","author":"X Chevalier","year":"2015","unstructured":"Chevalier, X. et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 74, 1697\u20131705 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR461","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12325-018-0751-8","volume":"35","author":"P Sarzi-Puttini","year":"2018","unstructured":"Sarzi-Puttini, P. et al. Clinical, ultrasound, and predictability outcomes following certolizumab pegol treatment (with methotrexate) in patients with moderate-to-severe rheumatoid arthritis: 52-week results from the CZP-SPEED study. Adv. Ther. 35, 1153\u20131168 (2018).","journal-title":"Adv. Ther."},{"key":"2556_CR462","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","volume":"290","author":"S Steeland","year":"2015","unstructured":"Steeland, S. et al. Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J. Biol. Chem. 290, 4022\u20134037 (2015).","journal-title":"J. Biol. Chem."},{"key":"2556_CR463","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1007\/s00216-016-9633-6","volume":"408","author":"Y Cao","year":"2016","unstructured":"Cao, Y. et al. Identification of a ligand for tumor necrosis factor receptor from Chinese herbs by combination of surface plasmon resonance biosensor and UPLC-MS. Anal. Bioanal. Chem. 408, 5359\u20135367 (2016).","journal-title":"Anal. Bioanal. Chem."},{"key":"2556_CR464","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1021\/acs.jcim.6b00672","volume":"57","author":"S Chen","year":"2017","unstructured":"Chen, S. et al. Discovery of novel ligands for TNF-\u03b1 and TNF receptor-1 through structure-based virtual screening and biological assay. J. Chem. Inf. Model. 57, 1101\u20131111 (2017).","journal-title":"J. Chem. Inf. Model."},{"key":"2556_CR465","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.intimp.2018.12.056","volume":"68","author":"C Lei","year":"2019","unstructured":"Lei, C. et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int. Immunopharmacol. 68, 68\u201373 (2019).","journal-title":"Int. Immunopharmacol."},{"key":"2556_CR466","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"JS Smolen","year":"2022","unstructured":"Smolen, J. S. et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N. Engl. J. Med. 387, 715\u2013726 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2556_CR467","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/RHU.0000000000000716","volume":"25","author":"A Leurs","year":"2019","unstructured":"Leurs, A. et al. Remission of refractory systemic-onset juvenile idiopathic arthritis after treatment with siltuximab. J. Clin. Rheumatol. 25, 40\u201342 (2019).","journal-title":"J. Clin. Rheumatol."},{"key":"2556_CR468","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1136\/annrheumdis-2017-211328","volume":"76","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi, T. et al. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann. Rheum. Dis. 76, 2001\u20132008 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR469","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"ME Weinblatt","year":"2015","unstructured":"Weinblatt, M. E. et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo\/active-controlled, dose-ranging study. Arthritis Rheumatol. 67, 2591\u20132600 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"2556_CR470","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40744-019-0157-3","volume":"6","author":"AF Wells","year":"2019","unstructured":"Wells, A. F. et al. Immunogenicity of sarilumab monotherapy in patients with rheumatoid arthritis who were inadequate responders or intolerant to disease-modifying antirheumatic drugs. Rheumatol. Ther. 6, 339\u2013352 (2019).","journal-title":"Rheumatol. Ther."},{"key":"2556_CR471","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.2169\/internalmedicine.1642-23","volume":"62","author":"R Fujita","year":"2023","unstructured":"Fujita, R. et al. Urosepsis risk in neuromyelitis optica spectrum disorder patients administered satralizumab. Intern. Med. 62, 3317\u20133320 (2023).","journal-title":"Intern. Med."},{"key":"2556_CR472","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/annrheumdis-2017-eular.3746","volume":"76","author":"T D\u00f6rner","year":"2017","unstructured":"D\u00f6rner, T. et al. FRI0239 results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis. Ann. Rheum. Dis. 76, 575 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR473","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116024","volume":"151","author":"YS Chiu","year":"2021","unstructured":"Chiu, Y. S. et al. The JAK inhibitor Tofacitinib inhibits structural damage in osteoarthritis by modulating JAK1\/TNF-alpha\/IL-6 signaling through Mir-149-5p. Bone 151, 116024 (2021).","journal-title":"Bone"},{"key":"2556_CR474","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1093\/rheumatology\/keac147","volume":"61","author":"Q Wang","year":"2022","unstructured":"Wang, Q., Chen, Z. & Dai, S. M. Baricitinib is a potential treatment in inflammatory osteoarthritis: a proof of concept study. Rheumatology 61, e213\u2013e215 (2022).","journal-title":"Rheumatology"},{"key":"2556_CR475","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00393-020-00750-1","volume":"79","author":"YH Lee","year":"2020","unstructured":"Lee, Y. H. & Song, G. G. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis. Z. Rheumatol. 79, 785\u2013796 (2020).","journal-title":"Z. Rheumatol."},{"key":"2556_CR476","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease, P. J. et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann. Rheum. Dis. 81, 815\u2013822 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"2556_CR477","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379, 1313\u20131321 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2556_CR478","doi-asserted-by":"publisher","first-page":"101989","DOI":"10.1016\/j.arr.2023.101989","volume":"90","author":"K Yamaura","year":"2023","unstructured":"Yamaura, K. et al. Therapeutic potential of senolytic agent quercetin in osteoarthritis: a systematic review and meta-analysis of preclinical studies. Ageing Res. Rev. 90, 101989 (2023).","journal-title":"Ageing Res. Rev."},{"key":"2556_CR479","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01069-5","volume":"21","author":"S Kan","year":"2023","unstructured":"Kan, S. et al. FGF19 increases mitochondrial biogenesis and fusion in chondrocytes via the AMPK\u03b1-p38\/MAPK pathway. Cell Commun. Signal. 21, 55 (2023).","journal-title":"Cell Commun. Signal."},{"key":"2556_CR480","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/13813455.2020.1727927","volume":"128","author":"D Chen","year":"2022","unstructured":"Chen, D., Guo, J. & Li, L. Catalpol promotes mitochondrial biogenesis in chondrocytes. Arch. Physiol. Biochem. 128, 802\u2013808 (2022).","journal-title":"Arch. Physiol. Biochem."},{"key":"2556_CR481","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13662","volume":"21","author":"D D\u2019Amico","year":"2022","unstructured":"D\u2019Amico, D. et al. Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis. Aging Cell 21, e13662 (2022).","journal-title":"Aging Cell"},{"key":"2556_CR482","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302475","volume":"12","author":"X Xia","year":"2023","unstructured":"Xia, X. et al. Retuning mitochondrial apoptosis\/mitophagy balance via SIRT3-energized and microenvironment-modulated hydrogel microspheres to impede osteoarthritis. Adv. Healthc. Mater. 12, e2302475 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"2556_CR483","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.911716","volume":"13","author":"R Xin","year":"2022","unstructured":"Xin, R. et al. Mitochonic acid-5 inhibits reactive oxygen species production and improves human chondrocyte survival by upregulating SIRT3-mediated, parkin-dependent mitophagy. Front. Pharmacol. 13, 911716 (2022).","journal-title":"Front. Pharmacol."},{"key":"2556_CR484","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102663","volume":"62","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. The physiological metabolite \u03b1-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress. Redox Biol. 62, 102663 (2023).","journal-title":"Redox Biol."},{"key":"2556_CR485","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615250","volume":"11","author":"R Mei","year":"2020","unstructured":"Mei, R. et al. 17\u03b2-estradiol induces mitophagy upregulation to protect chondrocytes via the SIRT1-mediated AMPK\/mTOR signaling pathway. Front. Endocrinol. 11, 615250 (2020).","journal-title":"Front. Endocrinol."},{"key":"2556_CR486","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110159","volume":"119","author":"G Yang","year":"2023","unstructured":"Yang, G. et al. Astaxanthin suppresses oxidative stress and calcification in vertebral cartilage endplate via activating Nrf-2\/HO-1 signaling pathway. Int. Immunopharmacol. 119, 110159 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"2556_CR487","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf1130","volume":"9","author":"B Chan","year":"2023","unstructured":"Chan, B. et al. Adseverin, an actin-binding protein, modulates hypertrophic chondrocyte differentiation and osteoarthritis progression. Sci. Adv. 9, eadf1130 (2023).","journal-title":"Sci. Adv."},{"key":"2556_CR488","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jcmm.13903","volume":"23","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway. J. Cell. Mol. Med. 23, 177\u2013193 (2019).","journal-title":"J. Cell. Mol. Med."},{"key":"2556_CR489","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04666-7","volume":"22","author":"R Peng","year":"2024","unstructured":"Peng, R. et al. Klf10 is involved in extracellular matrix calcification of chondrocytes alleviating chondrocyte senescence. J. Transl. Med. 22, 52 (2024).","journal-title":"J. Transl. Med."},{"key":"2556_CR490","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116855119","volume":"119","author":"J Elayyan","year":"2022","unstructured":"Elayyan, J. et al. Lef1 ablation alleviates cartilage mineralization following posttraumatic osteoarthritis induction. Proc. Natl. Acad. Sci. USA 119, e2116855119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2556_CR491","first-page":"59","volume":"32","author":"Y Ma","year":"2022","unstructured":"Ma, Y. et al. Anti-hypertrophic effect of synovium-derived stromal cells on costal chondrocytes promotes cartilage repairs. J. Orthop. Transl. 32, 59\u201368 (2022).","journal-title":"J. Orthop. Transl."},{"key":"2556_CR492","first-page":"521","volume":"41","author":"L Grossin","year":"2004","unstructured":"Grossin, L. et al. Induction of heat shock protein 70 (Hsp70) by proteasome inhibitor MG 132 protects articular chondrocytes from cellular death in vitro and in vivo. Biorheology 41, 521\u2013534 (2004).","journal-title":"Biorheology"},{"key":"2556_CR493","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1096\/fj.04-2889com","volume":"20","author":"L Grossin","year":"2006","unstructured":"Grossin, L. et al. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis. FASEB J. 20, 65\u201375 (2006).","journal-title":"FASEB J."},{"key":"2556_CR494","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/art.38000","volume":"65","author":"M Siebelt","year":"2013","unstructured":"Siebelt, M. et al. Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats. Arthritis Rheum. 65, 2102\u20132112 (2013).","journal-title":"Arthritis Rheum."},{"key":"2556_CR495","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/s12276-022-00879-w","volume":"54","author":"Z Zhu","year":"2022","unstructured":"Zhu, Z. et al. The natural product salicin alleviates osteoarthritis progression by binding to IRE1\u03b1 and inhibiting endoplasmic reticulum stress through the IRE1\u03b1-I\u03baB\u03b1-p65 signaling pathway. Exp. Mol. Med. 54, 1927\u20131939 (2022).","journal-title":"Exp. Mol. Med."},{"key":"2556_CR496","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1039\/C8FO01509K","volume":"9","author":"CL Xie","year":"2018","unstructured":"Xie, C. L. et al. Vitexin alleviates ER-stress-activated apoptosis and the related inflammation in chondrocytes and inhibits the degeneration of cartilage in rats. Food Funct. 9, 5740\u20135749 (2018).","journal-title":"Food Funct."},{"key":"2556_CR497","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1021\/acs.jafc.2c01773","volume":"70","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Safranal treatment induces Sirt1 expression and inhibits endoplasmic reticulum stress in mouse chondrocytes and alleviates osteoarthritis progression in a mouse model. J. Agric. Food Chem. 70, 9748\u20139759 (2022).","journal-title":"J. Agric. Food Chem."},{"key":"2556_CR498","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.453","volume":"8","author":"Q Tang","year":"2017","unstructured":"Tang, Q. et al. Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development. Cell Death Dis. 8, e3081 (2017).","journal-title":"Cell Death Dis."},{"key":"2556_CR499","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110724","volume":"384","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Dapagliflozin suppress endoplasmic reticulum stress mediated apoptosis of chondrocytes by activating Sirt1. Chem. Biol. Interact. 384, 110724 (2023).","journal-title":"Chem. Biol. Interact."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02556-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:03:04Z","timestamp":1772632984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02556-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":499,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02556-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}